CO-CRYSTALS AND SALTS OF 8-CHLOR-N-(4-(TRIFLUOROMETHOXYL)PHENYL)QUINOLIN-2-AMINE

Abstract

The present invention relates to pharmaceutically acceptable co-crystals and salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, to pharmaceutical compositions comprising them, and to their use as medicaments, and more particularly for use in the prevention and / or treatment of inflammatory diseases, viral diseases, and / or cancer or dysplasia. The present invention also relates to methods for preparing such pharmaceutically acceptable co-crystals and salts.

Description

CO-CRYSTALS AND SALTS OF 8-CHLORO-N-(4(TRIFLUQROMETHOXY) PHENYL) QUINOLIN-2-AMINE Field of Invention The present invention relates to the pharmaceutical field and more particularly to new co-crystals and new pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine (also called ABX464), to processes for their preparation, to their use as medicines and in particular to prevent and / or treat inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH (non-alcoholic steatohepatitis) and multiple sclerosis, diseases caused by a virus and / or cancer or dysplasia. The present invention also relates to pharmaceutical compositions comprising such cocrystals and / or pharmaceutically acceptable salts of 8-chloroN-(4-(trifluoromethoxy)phenyl)quinoline-2-amine. Background of the Invention Application WO2010 / 143169 describes the preparation and use of compounds and, in particular, quinoline derivatives including certain pharmaceutically acceptable salts useful in the treatment of HIV infection. In particular, such application describes 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine, also called rczonn / zznz / E / YiAi Ref. 335004 (8-chloro-quinolin-2-yl) -(4-trifluoromethoxy-phenyl)-amine, which is currently in clinical development. The inventors have stated that ABX464 is naturally highly crystalliferous and is therefore spontaneously present under a specific stable and unique crystal form called crystal form I. Application WO2017 / 158201 deals with certain mineral acids or sulfonic acid salts of ABX464. ABX464 has poor solubility in aqueous solutions. The main drawback of such poor solubility is that the active ingredient cannot completely achieve its objectives in the body if the drug remains undissolved in the gastrointestinal system. Therefore, there is a need to provide new means to improve the solubility of ABX464. Summary of the Invention Surprisingly, the inventors discovered that the implementation of new co-crystals and pharmaceutically acceptable salts of ABX464 provides new opportunities to improve the performance of a pharmaceutical product, for example, in terms of solubility and control of dissolution rate. Now, the inventors have developed new pharmaceutically acceptable salts and new co-crystals of ABX464. As mentioned above, there is always the need to improve the performance of a pharmaceutical product, for example in terms of solubility and more particularly when the free base is not soluble in water, as is the case with ABX464. . It has been observed that when the salts and co-crystals according to the present description are in suspension in water, due to the fact that the corresponding free base (i.e., 8-chloro-N-(4(trifluoromethoxy)phenyl) itself )quinolin-2-amine) is very weak, they dissociate and the free base tends to precipitate. Consequently, to avoid the formation of a precipitate and such instability during solubility measurements, these salts and cocrystals are classically formulated in the presence of at least one precipitation inhibitor as detailed below. As shown in the experimental part (example 10), the salts and co-crystals according to the present description surprisingly have a significantly higher solubility compared to the crystalline form I of ABX464 (i.e., the free base). Furthermore, Example 11 of the present description demonstrates that the salts according to the present description have a surprisingly significant superior solubility compared to crystalline form I of ABX464 (i.e., the free base) in an intestinal compartment model. Thus, the present invention aims to provide pharmaceutically acceptable cocrystals and salts of 8-chloro-N (4-(trifluoromethoxy)phenyl)quinolin-2-amine, as well as pharmaceutical compositions comprising such co-crystals and / or pharmaceutically acceptable salts of ABX464. that include a solvate and / or a hydrate thereof. Such co-crystals, the pharmaceutically acceptable salts of ABX464 and the pharmaceutical compositions containing them, can be used as a medicine and more particularly to treat and / or prevent inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH. (non-alcoholic steatohepatitis) and multiple sclerosis, diseases caused by a virus and / or cancer or dysplasia. The present invention thus provides co-crystals of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine which are chosen from: 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine: L-proline having a powder 20.6; 21.4; and 22.1 (each time ±0.2), and / or that has a single endotherm with a starting temperature of 172.0 °C (±2 °C); 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine: gentisic acid having an X-ray powder diffractogram showing peaks expressed as angle degrees 2theta to 7.9; 14.0; 15.2; and 25.2 (each time ±0.2), and / or having rczonn / zznz / E / YiAi a single endotherm with a starting temperature of 133.0 °C (±2 °C); 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine: malonic acid having an X-ray powder diffractogram showing peaks expressed as angle degrees 2theta to 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; and 25.6 (each time ±0.2), and / or that has a single endotherm with an onset temperature of 109.0 °C (±2 °C); and 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine: 4,4'-bipyridine having an X-ray powder diffractogram showing peaks expressed as degree angle 2Theta to 12.0; 19.2; 21.2; and 24.3 (each time ±0.2), and / or that has a single endotherm with a starting temperature of 127.0 °C (±2 °C). Therefore, the present invention also provides a pharmaceutically acceptable salt of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof which is selected from a lactate, oleate, oxalate, palmitate, stearate, valerate, pantothenate, picrate, butyrate, malonate, succinate, bitartrate, malate, mandelate, benzoate, edetate, gluceptate, gluconate, lactobionate, salicylate, disalicylate, mucate, pamoate, adipate, alginate, aspartate, camphorate, cyclopentanepropionate, digluconate, glucoheptonate, heptanoate, hexanoate, laurate, nicotinate, pamoate, pivalate, rczonn / zznz / E / YiAi propionate, undecanoate and the like, phosphate and the like, camphorsulfonate, 2-hydroxyethanesulfonate, estolate, napsylate, esylate, napadisylate , dodecyl sulfate and the like, perchloric acid, boric acid, glycerophosphoric acid, nitric acid, persulfuric acid and the like. Also provided here: - a method for preparing such 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine co-crystals as defined in the present invention; a method for preparing such pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein; - pharmaceutical compositions comprising such co-crystals as defined in the present invention and / or such pharmaceutically acceptable salts of ABX464 that include a solvate and / or a hydrate thereof as defined in the present invention and at least one pharmaceutically acceptable excipient ; - such pharmaceutically acceptable salt of ABX464 including a solvate and / or a hydrate thereof as defined in the present invention, such co-crystals as defined in the present invention or pharmaceutical compositions as defined in the present invention, for use as medicine; and - such pharmaceutically acceptable salt of ABX464 including a solvate and / or a hydrate thereof as defined in the present invention, such co-crystals as defined in the present invention or pharmaceutical compositions as defined in the present invention, for use in the prevention or treatment of cancer, AIDS, HIV infection and / or inflammatory diseases. A co-crystal is a crystalline complex composed of at least two neutral molecules linked in a crystal lattice through non-covalent interactions. The main difference between solvates and co-crystals is related to the physical state of the pure components: if one of the constituents is liquid at room temperature, the molecular complex is then a solvate; If all components are solid at room temperature, the complex is then designated by the term co-crystal. The main difference between a solvate and a co-crystal is the much greater stability of the co-crystals compared to the solvate. A cocrystal is characterized by the method by which it is obtained and by an ordered three-dimensional structure that is demonstrated, for example, by X-ray diffraction diagrams. It is not possible to know a priori whether two given constituents will be able to form a co-crystal that have a particular three-dimensional structure or will simply give rise to a juxtaposition of rczonn / zznz / E / YiAi the two powders. As used herein, the term pharmaceutically acceptable refers to those compounds, materials, excipients, carriers, adjuvants, vehicles, compositions or dosage forms that, within the scope of good medical judgment, are suitable for entry into contact with human and animal tissues without excessive toxicity, irritation, allergic response or other problematic complications consistent with a reasonable benefit / risk ratio. In the context of the invention, the term treat or treatment, as used herein, means to reverse, alleviate, inhibit the progress or prevent inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH (steatohepatitis). non-alcoholic) and multiple sclerosis, diseases caused by a virus and / or cancer or dysplasia. The term prevent, as used herein, means to reduce the risk of onset or slow down the onset of a given phenomenon, namely in the present invention, of inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH. (non-alcoholic steatohepatitis) and multiple sclerosis, diseases caused by rczonn / zznz / E / YiAi virus and / or cancer or dysplasia. As used here, prevent also includes reducing the likelihood that it will occur or reducing the likelihood that it will occur again. A subject (including the patient) includes mammals, for example, humans, companion animals (for example, dogs, cats, birds and the like), farm animals (for example, cows, sheep, pigs, horses, birds and the like). ) and laboratory animals (for example, rats, mice, guinea pigs, birds and the like). As used herein, the term room temperature or room temperature refers to a temperature ranging from 15°C to 30°C, more particularly from 18°C ​​to 25°C. Brief Description of the Figures Figure 1 is an Figure 2 is an Figure 3 is an Figure 4 is an rczonn / zznz / E / YiAi Figure 5 is an X-ray powder diagram of the anhydrous crystalline ABX464 hemi-napadisylate salt (see Example 5). Figure 6 is an X-ray powder diagram of the anhydrous crystalline ABX464 esylate salt (see Example 6). Figure 7 is an X-ray powder diagram of crystalline hemi-THF (tetrahydrofuran) solvate of ABX464 heminapadisylate (see Example 7). Figure 8 represents three powder X-ray diagrams, the first recorded for crystalline form I of ABX464 (see top line), the second recorded for solid waste collected at time point central), and the third recorded for solid residues collected at time point I 120 min in the intestinal compartment (see bottom line) of the fasting dissolution / precipitation tests performed for ABX464 crystalline form I. (See example 11). Figure 9 represents four powder third recorded for solid waste collected at time point G 30 min in the gastric compartment (see third numbered line from above), and fourth recorded for solid waste collected at time point I 120 min in the intestinal compartment (see bottom line, i.e. fourth numbered line from top) of fasting dissolution / precipitation tests performed for anhydrous ABX464 hemi-napadisylate salt. (See example 11). Detailed description of the invention As explained above, the inventors have demonstrated that the salts and co-crystals according to the present description show improved solubility compared to the solubility of crystalline form I of ABX464. As will be seen through Example 10 below, such improved solubility has been studied in two typical media FaSSIF (specifically, the simulated intestinal fluid in the fasted state) and FeSSIF (specifically, the simulated intestinal fluid in the fed state). As will be evident from such an example, an inhibitor or precipitation is also present in the medium, and specifically PVP-VA (polyvinylpyrrolidone-vinyl acetate). The use of such a precipitation inhibitor is classically used in the well-known spring and parachute approach. In fact, to improve the intestinal absorption of poorly water-soluble drugs, the concept of supersaturation in the gastrointestinal tract can be used as a strategy. To exploit supersaturation, two essential steps must be considered: the generation and maintenance of the metastable supersaturated state, which is also called the spring and parachute method (see Guzmán et al: A spring and parachute approach to designing solid celecoxib formulations having enhanced oral absorption. AAPS J 6, 2004, Abstract T2189). Once supersaturation (called spring) has been induced, drug molecules tend to precipitate, through processes that can be controlled kinetically or thermodynamically. To benefit from the supersaturated state, increased concentrations must be maintained for a period of time sufficient for absorption. This may require a temporary inhibition of precipitation by the use of pharmaceutical excipients or by other components that interfere with crystal nucleation and / or growth, i.e., parachutes or precipitation inhibitors. Among the precipitation inhibitors we can mention polymers such as PVP-VA (polyvinylpyrrolidone-vinyl acetate), HPMC (hydroxypropylmethylcellulose), HPMC-AS, HPMCP, surfactants such as TPGS (d-alpha-tocopheryl polyethylene glycol succinate 1000) or Pluronic ® F127 (also called rczonn / zznz / E / YiAi P407: poloxamer 407), hydroxypropyl cellulose (HPC), PVP (polyvinylpyrrolidone) such as PVP-K15, PVP-K30 or PVP-K90, Carbopol® 974P (highly carboxylated polymer composed of cross-linked polyacrylic acid), polyvinyl alcohol (PVA) and mixtures thereof, or sodium dodecyl sulfate may also be mentioned (SDS). As illustrated in example 10, a significantly higher solubility of all solid forms has been observed in the FeSSIF pH 5.0+ 1% PVPVA medium, mimicking the intestinal medium in the fed state. In other words, the presence of a precipitation inhibitor in such a medium prevents the precipitation of the free base of ABX464 but also opens the route to implement it in new pharmaceutical forms. Example 11, which tests the solubility behavior of a salt of ABX464 in a fasting human in vitro two-step dissolution-precipitation model (see, for example, Dressman et al., Estimating drug solubility in the gastrointestinal tract, Advanced Drug Delivery Reviews, 2007, volume 59, number 7, pages 591-602) further validates that the salts of ABX464 according to the present description demonstrate improved solubility compared to crystalline form I of ABX464. Indeed, a significantly higher rczonn / zznz / E / YiAi solubility of the hemi-napadisylate salt of ABX464 (-430 pg / ml) was clearly observed in the intestinal compartment compared to the solubility of the crystalline form I of ABX464 ( -80 pg / ml) in the intestinal compartment of this model. Therefore, the inventors have discovered new means to increase the solubility of ABX464, also to allow the preparation of a greater variety of galenic formulations ensuring that ABX464 achieves its biological target with the best bioavailability, as detailed below in the Compositions paragraph. Pharmaceuticals. The salts and co-crystals of the ABX464 subject matter of the present invention are described in more detail below. ABX464 Salts As mentioned above, an object of the present invention is a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof which is selects from lactate, oleate, oxalate, palmitate, stearate, valerate, pantothenate, picrate, butyrate, malonate, succinate, bitartrate, malate, mandelate, benzoate, edetate, gluceptate, gluconate, lactobionate, salicylate, disalicylate, mucate, pamoate, adipate, alginate, aspartate, camphorate, cyclopentanepropionate, digluconate, glucoheptonate, heptanoate, hexanoate, laurate, nicotinate, pamoate, pivalate, propionate, undecanoate and the like, phosphate and the like, camphorsulfonate, 2-hydroxyethanesulfonate, estolate, napsylate, esylate, napadisylate, dodecylsulfate and similar, rczonn / zznz / E / YiAi perchloric acid, boric acid, glycerophosphoric acid, nitric acid, persulfuric acid and the like, particularly selected from esylate and napadisylate, more particularly selected from an anhydrous crystalline ABX464 hemi-napadisylate salt, anhydrous crystalline ABX464 esylate salt, and crystalline ABX464 hemi-napadisylate hemi-THF solvate. Thus, according to one embodiment, such a pharmaceutically acceptable salt is anhydrous and is selected from the anhydrous crystalline ABX464 heminapadisylate salt and the anhydrous crystalline ABX464 esylate salt. Thus, according to another embodiment, such a pharmaceutically acceptable salt is in the form of a solvate or a hydrate, more particularly a solvate and even more particularly it is a crystalline hemi-THF (tetrahydrofuran) solvate of ABX464 hemi-napadisylate. Therefore, in a particular embodiment, a pharmaceutically acceptable salt of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention is selected from the anhydrous crystalline ABX464 heminapadisylate salt. , the anhydrous crystalline ABX464 esylate salt and the crystalline hemi-THF solvate of ABX464 hemi-napadisylate, as illustrated respectively in examples 5, 6 and 7 (and respectively in figures 5, 6 and 7) herein text. rczonn / zznz / E / YiAi In a particularly preferred embodiment, a pharmaceutically acceptable salt of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined herein is the anhydrous crystalline ABX464 hemi-napadisylate salt. Pharmaceutically acceptable salts of 8-chloroN-(4-(trifluoromethoxy)phenyl)quinoline-2-amine can be characterized, for example, by X-ray powder diffraction (XRPD) and by differential scanning calorimetry (DSC). in English) . More particularly, the anhydrous crystalline ABX464 hemi-napadisylate salt of Example 5 has an X-ray powder diffractogram showing peaks expressed as the angle of degrees 2-Theta at 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5 and 26.3 (each time ±0.2), and optionally also displays the following additional peaks expressed as 2-Theta degree angle: 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 25.2; and 25.9 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2), as illustrated in Figure 5 (X-ray powder diffractogram) and / or has a single endotherm with an initial temperature of 269.0 °C (±2 ’C). A characteristic X-ray powder diffractogram of a hemi-napadisylate salt of rczonn / zznz / E / YiAi can be given in Figure 5. Anhydrous crystalline ΑΒΧ464 and its characteristic signals are summarized in the following table 1: rczonn / zznz / E / YiAi Table 1 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 8.8 6 9.8 38 12.4 27 13.1 27 13.3 7 15.1 8 16.4 42 17.2 13 17.5 11 17.8 24 18.2 39 19.4 20 19.5 20 19.8 26 20.1 85 20.9 21 21.2 76 21.6 59 22.6 27 23.5 66 24.5 22 24.7 25 25.2 18 25.9 60 26.3 100 According to one embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least one peak expressed as a degree angle 2Theta selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5 ; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least two peaks expressed as a degree angle 2Theta selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least three peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 25.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least four peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; rczonn / zznz / E / YiAi 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 25.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time +0.2) . According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least five peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least six peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time +0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least seven peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each rczonn / zznz / E / YiAi time +0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least eight peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time +0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least nine peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least ten peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time +0.2) . rczonn / zznz / E / YiAi According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least eleven peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least twelve peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least thirteen peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 25.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 hemi napadisylate salt of the present invention presents an X-ray powder diffractogram showing at least fourteen peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 2 5.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention presents an X-ray powder diffractogram showing at least fifteen peaks expressed as a 2-Theta degree angle selected from 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5; 26.3; 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 25.2; 25.9; 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 heminapadisylate salt of the present invention has an XRPD substantially similar to that depicted in Figure 5. More particularly, the anhydrous crystalline ABX464 esylate salt of Example 6 has an X-ray powder diffractogram showing peaks expressed as angle degrees 2-Theta to 12.2; and 22.2 (each time ±0.2), and optionally also displays the following additional peaks expressed as 2-Theta degree angle: 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; and 20.7 (each time ±0.2); and even optionally rczonn / zznz / E / YiAi plus the following additional peaks expressed as 2-Theta degree angle: 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time +0.2), as illustrated in Figure 6 (X-ray powder diffractogram) and / or has a single endotherm with an initial temperature of 108.0 °C (±2 °C). A characteristic X-ray powder diffractogram of an anhydrous crystalline ABX464 esylate salt can be given in Figure 6 and its characteristic signals are summarized in the following Table 2: rczonn / zznz / E / YiAi Table 2 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 6.2 13 10.1 9 12.2 100 12.9 17 13.1 11 15.3 27 15.8 11 16.3 13 17.7 14 17.9 14 18.2 16 18.6 15 19.5 47 20.0 49 20.3 15 20.7 23 21.4 15 22.2 85 According to one embodiment, the esylate salt of Anhydrous crystalline ABX464 of the present invention presents an X-ray powder diffractogram showing at least one peak expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least two peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least three peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention exhibits an X-ray powder diffractogram showing at least four peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each rczonn / zznz / E / YiAi time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least five peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least six peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention exhibits an X-ray powder diffractogram showing at least seven peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least eight rczonn / zznz / E / YiAi peaks expressed as a 2-Theta degree angle selected from 12.2 ; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time +0.2) . According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention exhibits an X-ray powder diffractogram showing at least nine peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least ten peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time +0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least eleven peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time +0.2) . According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least twelve peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least thirteen peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time +0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least fourteen peaks expressed as a 2-Theta degree angle selected from 12.2; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention presents an X-ray powder diffractogram showing at least fifteen peaks expressed as a 2-Theta degree angle selected rczonn / zznz / E / YiAi between 12.2 ; 22.2; 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; 20.7; 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2). According to another embodiment, the anhydrous crystalline ABX464 esylate salt of the present invention has an XRPD substantially similar to that depicted in Figure 6. More particularly, the crystalline hemi-THF solvate of the hemi-napadisylate salt of ABX464 of Example 7 has an X-ray powder diffractogram showing peaks expressed as angle degrees 2-Theta to 8.4; 12.3; 14.0; 19.2; 21.3; 22.6 and 24.6 (each time ±0.2), and optionally also displays the following additional peaks expressed as 2-Theta degree angle: 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9 and 25.2 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2), as illustrated in Figure 7 (X-ray powder diffractogram) and / or has a single endotherm with an initial temperature of 172.0 °C (±2 °C). A characteristic X-ray powder diffractogram of a crystalline hemi-THF solvate of the ABX464 hemi-napadisylate salt can be given in Figure 7 and its characteristic signals are summarized in the following Table 3: rczonn / zznz / E / YiAi Table 3 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 8.4 93 9.6 10 12.3 46 13.0 13 13.5 14 14.0 22 14.8 9 16.7 5 17.2 10 17.8 26 18.1 8 18.8 7 19.2 59 1 9.5 9 20.9 9 21.3 32 22.3 12 22.6 47 23.4 10 24.1 13 24.6 100 24.9 31 25.2 21 According to one embodiment, the crystalline hemi-THF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least one peak expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2) . According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least two peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2) . According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least three peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2) . According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least four peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). rczonn / zznz / E / YiAi According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least five peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least six peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least seven peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). According to another embodiment, the hemi solvate Crystalline THF of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least eight peaks expressed as 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2) . According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least nine peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least ten peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least eleven peaks expressed as an angle of degrees 2-Theta selected between 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 2 3.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least twelve peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2). According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least thirteen peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2) . According to another embodiment, the crystalline hemi-THF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least fourteen peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time +0.2). According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention presents an X-ray powder diffractogram showing at least fifteen peaks expressed as a 2-Theta degree angle selected from 8.4; 12.3; 14.0; 19.2; 21.3; 22.6; 24.6; 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9; 25.2; 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time +0.2) . According to another embodiment, the crystalline hemiTHF solvate of the hemi-napadisylate salt of ABX464 of the present invention has an XRPD substantially similar to that depicted in Figure 7. Method for preparing a pharmaceutically acceptable salt of ABX464 Further provided herein is a method for preparing a pharmaceutically acceptable salt of ABX464 (including solvates or hydrates thereof) comprising the following steps: a) dissolve ABX464 in a solvent or in a mixture of rczonn / zznz / E / YiAi solvents; b) add to the mixture thus obtained from step a) a counterion in the form of an acid that may itself be already dissolved in a solvent or in a mixture of solvents to obtain an ABX464:counterion molar ratio between 3:1 and 1: 2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent(s) at a temperature between 0 °C and the boiling point of the selected solvent(s) or the solvent mixture(s) from step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally add a solvent or a mixture of solvents, e) apply a temperature program; f) optionally filter; and g) then optionally dry at a temperature between room temperature and 60 °C to obtain the desired salt of ABX464. According to one embodiment, the solvent(s) used in step a), step b) and step d) is (are) any solvent conventionally used in the crystallization step, particularly it is ( are) organic solvents, more particularly it is (are) selected from an aliphatic Ci-Ce rczonn / zznz / E / YiAi alcohol, methyl ethyl ketone (also called butanone or MEK), cyclohexane, an alkane such as heptane, chloride methylene, chloroform, formic acid, DMSO, l-methyl-2pyrrolidone, acetone, acetonitrile, tetrahydrofuran (THE), diethyl ether, dioxane, toluene, ethyl acetate, optionally in mixture with water, and mixtures thereof, even more particularly selected from a Ci-C6 aliphatic alcohol, a mixture of HzO / Ci-Cs aliphatic alcohol, and mixtures thereof, even more particularly selected from methanol, ethanol, isopropanol, EbO / methanol, EbO / ethanol, and mixtures thereof . The person skilled in the art will know how to determine the most appropriate solvent(s) in each step a), b) and d) to obtain the desired pharmaceutically acceptable salt. According to one embodiment, the solvent(s) used in step a), step b) and / or step d) is (are) the same. According to another embodiment, the solvent(s) used in step a), step b) and / or step d) is (are) different. Advantageously, the counterion in acid form of step b) is ethanesulfonic acid or naphthalene-1,5disulfonic acid. Thus, in some embodiments, the solvent of step a), step b) and / or step d) is any solvent conventionally used in the crystallization step, particularly organic solvents, more particularly selected from a Ci-Cg aliphatic alcohol, methyl ethyl ketone (also called butanone or MEK), cyclohexane, an alkane such as heptane, methylene chloride, chloroform, formic acid, DMSO, l-methyl-2-pyrrolidone, acetone, acetonitrile, tetrahydrofuran ( THE), diethyl ether, dioxane, toluene, ethyl acetate, optionally mixed with water, and mixtures thereof, even more particularly selected from a Ci-Ce aliphatic alcohol, a mixture of H2O / Ci-Ce aliphatic alcohol, and mixtures thereof, even more particularly selected from methanol, ethanol, isopropanol, H20 / methanol, lUO / ethanol and mixtures thereof; and / or the counterion in acid form of step b) is ethanesulfonic acid or naphthalene-1,5-disulfonic acid. According to one embodiment, evaporation step c) is carried out under an inert gas such as N2. According to one embodiment, step e) relating to the temperature program includes a reflux heating phase at a temperature between room temperature and the boiling point of the solvent(s), particularly between room temperature and 60°C. According to one embodiment, step e) relating to the temperature program includes a reflux cooling phase at a temperature between 0°C and 60°C, particularly rczonn / zznz / E / YiAi between 5°C and 40°C, more particularly between room temperature and 40 °C at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min. According to one embodiment, step e) relating to the temperature program includes i) heating under reflux at a temperature between room temperature and the boiling point of the solvent(s), particularly between room temperature and 60°C and / or ii) reflux cooling at a temperature between 0 °C and 60 °C, particularly between 5 °C and 40 °C, more particularly between room temperature and 40 °C at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min. According to a particular embodiment, step e) relating to the temperature program includes i) reflux heating at a temperature between room temperature and 60°C and ii) reflux cooling at a temperature between 5°C and 40°C. °C, at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min. According to one embodiment, step f) relating to filtration is carried out using conventional glass fibers, conventional cellulosic filter papers, PTFE rczonn / zznz / E / YiAi (polytetrafluoroethylene), or PVDF (polyvinylidene fluoride), in particular cellulosic filter paper with a filtration mesh of 0.45 pm or 0.2 pm. According to one embodiment, drying step g) is carried out under vacuum at a temperature between 30°C and 60°C, particularly at 40°C. According to one embodiment, drying step g) is carried out in an ambient atmosphere at a temperature between 30°C and 60°C, particularly at 40°C. It is understood that for the preparation of a pharmaceutically acceptable salt of ABX464 as defined in the present invention, 8-chloroN-(4-(trifluoromethoxy)phenyl)quinolin-2-amine can be previously obtained either from a process such as one described in WO2010 / 143169 or any other appropriate process. According to some embodiments, the method for preparing a pharmaceutically acceptable salt of ABX464 (including solvates or hydrates thereof) comprises the following steps: a) dissolve ABX464 in a solvent or in a mixture of solvents; b) add to the mixture thus obtained from step a) a counterion in the form of an acid that may already be dissolved in a solvent or in a mixture of solvents to obtain a molar ratio of ABX464:counterion between 3:1 and rczonn / zznz / E / YiAi 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent (s) at a temperature between 0 ° C and the boiling point of the selected solvent (s) or mixture of solvent (s) from step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally add a solvent or a mixture of solvents, e) apply a temperature program that includes i) reflux heating at a temperature between room temperature and the boiling point of the solvent(s), particularly between room temperature and 60 °C and / or ii) cooling at reflux at a temperature between 0 °C and 60 °C, particularly between 5 °C and 40 °C, more particularly between room temperature and 40 °C at a speed between 30 °C / min and 0.05 °C / min , particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min; f) optionally filtering using conventional glass fibers, conventional cellulose filter papers, PTFE (polytetrafluoroethylene) or PVDF (polyvinylidene fluoride), particularly cellulose filter paper with 0.45 pm or 0.2 pm filtration mesh; and rczonn / zznz / E / YiAi g) then optionally dry under vacuum at a temperature between 30 °C and 60 °C, particularly at 40 °C or under ambient atmosphere at a temperature between 30 °C and 60 °C, particularly at 40 °C to obtain the desired salt from ABX464. According to some embodiments, the method for preparing a pharmaceutically acceptable salt of ABX 464 comprises the following steps: a) dissolve ABX464 in methanol; b) add to the mixture thus obtained from step a) a counterion that is ethanesulfonic acid or naphthalenesulfonic acid that is already dissolved in water / ethanol or ethanol to obtain an ABX464:counterion molar ratio between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent (s) at a temperature between 0 ° C and the boiling point of the selected solvent (s) or mixture of solvent (s) from step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally adding a solvent selected from ethyl acetate, THF, acetone and mixtures thereof, e) apply a temperature program that includes rczonn / zznz / E / YiAi (i) a reflux heating phase at a temperature between room temperature and the boiling point of the solvent (), particularly between room temperature and 60 °C and / or (ii) a reflux cooling phase at a temperature between 0 °C and 60 °C, particularly between 5 °C and 40 °C, more particularly between room temperature and 40 °C at a speed comprised between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min; f) optionally filter; and g) then optionally dry at a temperature between room temperature and 60 °C to obtain the desired salt of ABX464. According to some embodiments, the method for preparing a pharmaceutically acceptable salt of ABX 464 comprises the following steps: a) dissolve ABX464 in methanol; b) add to the mixture thus obtained from step a) a counterion that is ethanesulfonic acid or naphthalenesulfonic acid that is already dissolved in water / ethanol or ethanol to obtain a molar ratio of ABX464: counterion between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent (s) at a temperature between 0 °C and the boiling point of the selected solvent (s) or solvent mixture (s). ) of step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally adding a solvent selected from ethyl acetate, THF, acetone and mixtures thereof, e) apply a temperature program that includes (i) a reflux heating phase at a temperature of 60 °C and / or (ii) a reflux cooling phase at a temperature of 5 °C and 40 °C, plus particularly between ambient temperature and 40 °C at a rate of 1 °C / min; f) optionally filter; and g) then optionally dry at 40°C to obtain the desired ABX464 salt. According to a particular embodiment, ABX464 is dissolved in an aliphatic Ci-Cg alcohol, in particular methane!, then naphthalene-1,5-disulfonic acid is added to this mixture, which in turn is already dissolved in an aliphatic Ci alcohol. -Ce, in particular ethanol so that a molar ratio of ΆΒΧ464:counterion between 3:1 and 1:2, particularly between 5:2 and 1:2, can be obtained; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1. Evaporation is then carried out under N2 at room temperature (25 °C), then the addition of acetone, then the application of a rczonn / zznz / E / YiAi temperature program before filtration at 0.2 pm and drying at vacuum at 40 °C to obtain the anhydrous crystalline ABX464 heminapadisylate salt. According to another particular embodiment, ABX464 is dissolved in a Ci-Ce aliphatic alcohol, in particular methanol, then ethanesulfonic acid is added to this mixture, which in turn is already dissolved in a mixture of H20 / Ci-aliphatic alcohol. Cg, in particular water / ethanol to obtain a molar ratio of ABX464:counterion between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 1:1. Evaporation is then carried out under N2 at room temperature (25 °C), then the addition of ethyl acetate, then the application of a temperature program before evaporation carried out under N2 at room temperature (25 °C) to obtain the anhydrous crystalline ABX464 esylate salt. According to another embodiment, ABX464 is dissolved in an aliphatic Ci-Ce alcohol, in particular methanol, then naphthalene-1,5-disulfonic acid is added to this mixture, which in turn is already dissolved in an aliphatic Ci alcohol. -Ce, in particular ethanol so as to obtain a molar ratio of ABX464: counterion between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1. It is then evaporated under N2 at 40 °C, then THF is added, then a rczonn / zznz / E / YiAi temperature program is applied before filtration at 0.2 pm and vacuum drying is carried out at 40 °C to obtain a crystalline hemi-THF solvate of hemi-napadisylate from ABX464. ABX464 co-crystals As mentioned above, in another aspect, the present invention relates to co-crystals of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine which are chosen from: 8-chloro-N-(4 -(trifluoromethoxy)phenyl)quinoline-2amine: L-proline having an X-ray powder diffractogram showing peaks expressed as angle degrees 2Theta to 16.5; 20.6; 21.4; and 22.1 (each time ±0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 11.0; 15.9; 18.3; and 19.4 (each time ±0.2); and even optionally further the following additional peaks expressed as degree angle 2-Theta 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 1 and / or having a single endotherm with an onset temperature of 172.0 °C (±2 °C ); 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine: gentisic acid having an X-ray powder diffractogram showing peaks expressed as angle degrees 2theta to 7.9; 14.0; 15.2; and 25.2 (each time ±0.2), and which can optionally also display the following additional rczonn / zznz / E / YiAi peaks expressed as a 2-Theta degree angle: 15.8; 16.9; 18.5; 19.9; 20.3; 23.0 and 24.7 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 2 and / or having a single endotherm with an onset temperature of 133.0 °C (±2 °C) ; 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine: malonic acid having an X-ray powder diffractogram showing peaks expressed as angle degrees 2Theta to 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; and 25.6 (each time ±0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 19.0; 21.4; 24.6; 26.8; 27.6; and 29.9 (each time ±0.2); and even optionally further the following additional peaks expressed as degree angle 2-Theta 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 3 and / or having a single endotherm with an onset temperature of 109.0 °C (±2 °C) ; and 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine: 4,4'-bipyridine having an X-ray powder diffractogram showing peaks expressed as degree angle 2Theta to 12.0; 19.2; 21.2; and 24.3 (each time +0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 16.0; 17.0; 17.8; 20.3; 22.5; and 22.7 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 4 and / or having a single endotherm with an onset temperature of 127.0 °C (±2 °C ). In a particularly preferred embodiment, a cocrystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine is 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine: L-proline which has an X-ray powder diffractogram showing peaks expressed as angle degrees 2Theta to 16.5; 20.6; 21.4; and 22.1 (each time ±0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 11.0; 15.9; 18.3; and 19.4 (each time ±0.2); and even optionally further the following additional peaks expressed as degree angle 2-Theta 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 1 and / or having a single endotherm with an onset temperature of 172.0 °C (+2 ° C). Such four co-crystals are illustrated respectively in examples 1 (and figure 1), 2 (and figure 2), 3 (and figure 3) and 4 (and figure 4) of the present text. A characteristic the following table 4: rczonn / zznz / E / YiAi Table 4 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 6.1 5 11.0 8 12.2 10 12.6 8 13.3 9 13.7 8 15.4 4 15.9 9 16.5 20 17.3 8 18.3 17 19.4 33 20.6 100 21. 4 31 22.1 38 22.4 10 According to one embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention exhibits an X-ray powder diffractogram showing at least one expressed peak. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2) . According to another embodiment, the 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine:Lproline co-crystal of the present invention presents an X-ray powder diffractogram showing at least two peaks expressed as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2). According to another embodiment, the 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine:Lproline co-crystal of the present invention presents an X-ray powder diffractogram showing at least three peaks expressed as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2). According to another embodiment, the 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine:Lproline co-crystal of the present invention presents an X-ray powder diffractogram showing at least four peaks expressed as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least five expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least six expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time +0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least seven expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least eight expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; rczonn / zznz / E / YiAi 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time +0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least nine expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time +0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least ten expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least eleven expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2) . According to another embodiment, the 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine: L rczonn / zznz / E / YiAi proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least twelve peaks expressed as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2). According to another embodiment, the 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine:Lproline co-crystal of the present invention presents an X-ray powder diffractogram showing at least thirteen peaks expressed as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least fourteen expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention presents an X-ray powder diffractogram showing at least fifteen expressed peaks. as 2-Theta degree angle selected from 16.5; 20.6; 21.4; 22.1; 11.0; 15.9; 18.3; 19.4; 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal of the present invention has an XRPD substantially similar to that depicted in Figure 1. A characteristic table 5 below: rczonn / zznz / E / YiAi Table 5 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 7.6 12 7.9 60 14.0 33 14.7 11 15.2 78 15.8 41 16.1 16 16.9 28 18.5 23 19.7 17 19.9 26 20.3 43 21.6 13 22.0 25 22.3 20 23.0 27 23.7 25 24.0 33 24.7 45 25.2 100 According to one embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least one peak expressed as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 23.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least two expressed peaks. as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 23.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid of the present invention presents an X-ray powder diffractogram showing at least three peaks expressed as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 23.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the co-crystal of 8-chloro-N- (4 (trifluoromethoxy) phenyl) quinolin-2-amine: gentisic acid of the present invention presents an X-ray diffractogram in rczonn / zznz / E / YiAi powder that shows at least eleven peaks expressed as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 23.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least twelve peaks expressed as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 23.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid of the present invention presents an X-ray powder diffractogram showing at least thirteen peaks expressed as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 23.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least fourteen expressed peaks. as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 2 3.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid of the present invention presents an X-ray powder diffractogram showing at least fifteen peaks expressed as 2-Theta degree angle selected from 7.9; 14.0; 15.2; 25.2; 15.8; 16.9; 18.5; 19.9; 20.3; 23.0; 24.7; 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:gentisic acid co-crystal of the present invention has an XRPD substantially similar to that depicted in Figure 2. A characteristic table 6 below: rczonn / zznz / E / YiAi Table 6 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 9.5 26 12.2 34 15.8 38 16.8 7 17.3 42 17.8 7 19.0 22 19.7 47 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 20.9 6 21.4 27 22.8 65 23.8 11 24.6 76 24.8 100 25.6 54 26.8 18 27.6 31 28.0 11 29.6 13 29.9 25 rczonn / zznz / E / YiAi According to one embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least one peak expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 29.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least two peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 29.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least three peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least four peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least five peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least six peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; rczonn / zznz / E / YiAi 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least seven peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least eight peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least nine peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine: malonic acid of the present invention presents an X-ray powder diffractogram that shows at least ten peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least eleven peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least twelve peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 2 9.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N(4-(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder difraethogram showing at least thirteen peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 29.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N(4-(trifluoromethoxy)pheni1)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least fourteen peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 29.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N(4-(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention presents an X-ray powder diffractogram showing at least fifteen peaks expressed as 2-Theta degree angle selected from 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; 25.6; 19.0; 21.4; 24.6; 26.8; 27.6; 29.9; 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid co-crystal of the present invention has an XRPD substantially similar to that depicted in Figure 3. A characteristic X-ray powder diffractogram of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine: 4,4'-bipyridine and its rczonn / zznz / E / YiAi signal characteristics are summarized in the following table 7: rczonn / zznz / E / YiAi Table 7 Angle (2-Theta) (each time ±0.2) Relative intensity (%) 8.5 5 12.0 16 13.0 7 15.7 7 16.0 12 16.7 9 17.0 30 17.8 16 19.2 40 20.3 14 20.9 11 21.2 100 22.0 8 22.5 21 22.7 21 23.1 10 23.6 12 24.3 36 24.7 10 According to one embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention exhibits an X-ray powder diffractogram showing at least a peak expressed as a 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least two peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least three peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 2 0.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least four peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 2 0.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least five peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4 rczonn / zznz / E / YiAi (trifluoromethoxy)phenyl)quinolin-2-amine:4,4'-bipyridine co-crystal of the present invention presents a ray diffractogram X powder showing at least six peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least seven peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 2 0.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least eight peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least nine peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; rczonn / zznz / E / YiAi 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least ten peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 2 0.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least eleven peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least twelve peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine: 4,4'-bipyridine of rczonn / zznz / E / YiAi the present invention presents a ray diffractogram X powder showing at least thirteen peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 2 0.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least fourteen peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2). According to another embodiment, the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal of the present invention presents an X-ray powder diffractogram showing at least fifteen peaks expressed as 2-Theta degree angle selected from 12.0; 19.2; 21.2; 24.3; 16.0; 17.0; 17.8; 20.3; 22.5; 22.7; 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2) . According to another embodiment, the 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine:4,4'bipyridine co-crystal of the present invention has an XRPD substantially similar to that depicted in Figure 4. ABX464 co-crystal preparation method According to another aspect, the present invention rczonn / zznz / E / YiAi further relates to a method for preparing a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as follows. defines in the present invention that it comprises the following steps of: a) dissolve ABX464 in a solvent or in a mixture of solvents; b) add to the mixture thus obtained from step a) a co-former which may itself be already dissolved in a solvent or in a mixture of solvents and which is selected from L-proline, gentisic acid, malonic acid and 4,4 'bipyridine to obtain a co-former of ABX464 in a molar ratio between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent(s) at a temperature between 0 °C and the boiling point of the selected solvent(s) or solvent mixture(s) from step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally add a solvent or a mixture of solvents, e) apply a temperature program; f) optionally filter; and g) then, optionally, dry at a rczonn / zznz / E / YiAi temperature between room temperature and 60 °C to obtain the desired co-crystal of ABX464. According to one embodiment, the solvent(s) used in step a), step b) and step d) is (are) any solvent conventionally used in the crystallization step, particularly it is ( are) organic solvents, more particularly it is (are) selected from an aliphatic Ci-Ce alcohol, methyl ethyl ketone (also called butanone or MEK), cyclohexane, an alkane such as heptane, methylene chloride, chloroform, formic acid, DMSO, l-methyl-2pyrrolidone, acetone, acetonitrile, tetrahydrofuran (THE), diethyl ether, dioxane, toluene, ethyl acetate, optionally in mixture with water, and mixtures thereof, even more particularly selected from an aliphatic alcohol of Ci -Ce, a mixture of H20 / Ci-Ce aliphatic alcohol, acetonitrile and mixtures thereof, even more particularly selected from methanol, ethanol, isopropanol, H20 / methanol, H20 / ethanol, acetonitrile, and mixtures thereof. The person skilled in the art will know how to determine the most appropriate solvent(s) in each step a), b) and d) to obtain the desired co-crystal. According to one embodiment, the solvent(s) used in step a), step b) and / or step d) is (are) the same. rczonn / zznz / E / YiAi According to another embodiment, the solvent(s) used in step a), step b) and / or step d) is (are) different. According to one embodiment, evaporation step c) is carried out under an inert gas such as N2. According to one embodiment, step e) relating to the temperature program includes a reflux heating phase at a temperature between room temperature and the boiling point of the solvent(s), particularly between room temperature and 60°C. According to one embodiment, step e) relating to the temperature program includes a reflux cooling phase at a temperature between 0°C and 60°C, particularly between 5°C and 40°C, more particularly between room temperature and 40°C. °C at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min. According to one embodiment, step e) relating to the temperature program includes i) heating under reflux at a temperature between room temperature and the boiling point of the solvent(s), particularly between room temperature and 60°C and / or ii) reflux cooling at a temperature between 0 °C and 60 °C, particularly between 5 °C and 40 °C, more particularly between room temperature and 40 °C at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and rczonn / zznz / E / YiAi 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min. According to a particular embodiment, step e) relating to the temperature program includes i) reflux heating at a temperature between room temperature and 60°C and ii) reflux cooling at a temperature between 5°C and 40°C. °C, at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min. According to one embodiment, step f) relating to filtration is carried out using conventional glass fibers, conventional cellulosic filter papers, PTFE (polytetrafluoroethylene), or PVDF (polyvinylidene fluoride), in particular cellulosic filter paper with a filtration mesh of 0.45 pm. or 0.2 pm. According to one embodiment, drying step g) is carried out in a vacuum at a temperature between 30°C and 60°C, particularly at 40°C. According to one embodiment, drying step g) is carried out in an ambient atmosphere at a temperature between 30°C and 60°C, particularly at 40°C. According to a particular embodiment, the method of preparing a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention comprises the following steps of: rczonn / zznz / E / YiAi a) dissolve ABX464 in a solvent or in a mixture of solvents; b) add to the mixture thus obtained from step a) a co-former which may itself be already dissolved in a solvent or in a mixture of solvents and which is selected from L-proline, gentisic acid, malonic acid and 4,4 '—bipyridine to obtain a co-former of ABX464 in a molar ratio between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent (s) at a temperature between 0 ° C and the boiling point of the selected solvent (s) or solvent mixture (s) from step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally add a solvent or a mixture of solvents, e) apply a temperature program that includes i) reflux heating at a temperature between room temperature and 60 °C and / or ii) reflux cooling at a temperature between 5 °C and 40 °C, at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min; f) optionally filtering using conventional glass fibers, conventional cellulose filter papers, PTFE (polytetrafluoroethylene) or PVDF (polyvinylidene fluoride), particularly cellulose filter paper with 0.45 pm or 0.2 pm filtration mesh; and g) then optionally dry under vacuum at a temperature between 30 °C and 60 °C, particularly at 40 °C or under ambient atmosphere at a temperature between 30 °C and 60 °C, particularly at 40 °C to obtain the desired co-crystal of ABX464. According to another particular embodiment, the method of preparing a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention comprises the following steps of: a) dissolve ABX464 in methanol, ethanol, isopropanol, H2O / methanol, H2O / ethanol, acetonitrile or mixtures thereof; b) add to the mixture thus obtained from step a) a co-former that may already be dissolved in methanol, ethanol, isopropanol, H20 / methanol, H2O / ethanol, acetonitrile or mixtures thereof and which is selected from L-proline , gentisic acid, malonic acid and 4,4'-bipyridine to obtain an ABX464:co-former in a molar ratio between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent (s) at a temperature between 0 ° C and the boiling point of the selected solvent (s) or solvent mixture (s) from step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally adding a solvent selected from methanol, ethanol, isopropanol, H20 / methanol, H?0 / ethanol, acetonitrile and mixtures thereof, e) apply a temperature program; f) optionally filter; and g) then, optionally, dry at a temperature between room temperature and 60 ° C to obtain the desired co-crystal of ABX464. According to another particular embodiment, the method of preparing a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention comprises the following steps of: a) dissolve ABX464 in methanol, ethanol, isopropanol, H20 / methanol, H2O / ethanol, acetonitrile or mixtures thereof; b) add to the mixture thus obtained from step a) a co-former that may already be dissolved in methanol, ethanol, isopropanol, H20 / methanol, H2O / ethanol, acetonitrile or mixtures thereof and which is selected from L-proline , rczonn / zznz / E / YiAi gentisic acid, malonic acid and 4,4'-bipyridine to obtain an ABX464: co-former in a molar ratio between 3:1 and 1:2, particularly between 5:2 and 1: 2; more particularly between 2:1 and 1:2, and even more particularly it is 2:1 or 1:1; c) optionally evaporate the solvent(s) at a temperature between 0 °C and the boiling point of the selected solvent(s) or mixture of solvent(s) from step a) and step b), particularly between room temperature and 60°C, more particularly between room temperature and 50°C; d) optionally adding a solvent selected from methanol, ethanol, isopropanol, H20 / methanol, H20 / ethanol, acetonitrile and mixtures thereof, e) apply a temperature program that includes i) reflux heating at a temperature between room temperature and 60 °C and / or ii) reflux cooling at a temperature between 5 °C and 40 °C, at a speed between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min; f) optionally filtering using conventional glass fibers, conventional cellulose filter papers, PTFE (polytetrafluoroethylene) or PVDF (polyvinylidene fluoride), particularly cellulose filter paper with 0.45 pm or 0.2 pm filtration mesh; and rczonn / zznz / E / YiAi g) then optionally dry under vacuum at a temperature between 30 °C and 60 °C, particularly at 40 °C or under ambient atmosphere at a temperature between 30 °C and 60 °C, particularly at 40 °C to obtain the desired co-crystal of ABX464. According to another aspect, the present invention further relates to a method for preparing a co-crystal of 8-chloro-N(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention comprising the steps of : a') physically mix 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine with a co-former chosen from L-proline, gentisic acid, malonic acid and 4,4'-bipyridine at a proportion molar between 2:1 and 1:2, particularly in a 1:1 molar ratio, in a suitable solvent or mixtures of solvents; and - b') grinding of the physical mixture thus obtained from step a), in the presence of a drop of solvent or mixtures of solvents to obtain the co-crystal. The person skilled in the art may know how to determine the most appropriate solvent(s) in each step a') and b') to obtain the desired co-crystal. According to one embodiment, the solvent(s) used in step a') and step b') is (are) any solvent conventionally used in the crystallization step, particularly it is (are) solvents organic, more rczonn / zznz / E / YiAi particularly is (are) selected from an aliphatic alcohol of Ci-C&, methyl ethyl ketone (also called butanone or MEK), cyclohexane, an alkane such as heptane, methylene chloride, chloroform , formic acid, DMSO, l-methyl-2pyrrolidone, acetone, acetonitrile, tetrahydrofuran (THF), diethyl ether, dioxane, toluene, ethyl acetate, optionally in mixture with water, and mixtures thereof, even more particularly selected from a Ci-Ce aliphatic alcohol, a mixture of H^O / Ci-Cg aliphatic alcohol, acetonitrile, and mixtures thereof, even more particularly selected from methanol, ethanol, isopropanol, H2O / methanol, fbO / ethanol, acetonitrile, and mixtures thereof. In some embodiments, grinding is carried out using a Retsch MM200 instrument for a 45 min grind at 20 Hz. According to one embodiment, the grinding is carried out by using non-oxidisable balls. According to one embodiment, the crushing is carried out by horizontal movements, in particular horizontal movements having a frequency ranging between 20 and 30 Hz. Advantageously, the horizontal movements are applied for a period that may range between 15 minutes and 3 hours, in particular 45 minutes. According to a particular embodiment, the present invention further relates to a method of preparing a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention that comprises the steps of: a') physically mix the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine with a co-former chosen from L-proline, gentisic acid, malonic acid and 4,4'bipyridine at a molar ratio between 2:1 and 1:2, particularly at a 1:1 molar ratio, in a suitable solvent selected from methane, ethanol, isopropanol, H2O / methanol, H2O / ethanol, acetonitrile and mixtures thereof; and - b') grinding of the physical mixture thus obtained from step a), in the presence of a drop of solvent that is selected from methanol, ethanol, isopropanol, H2O / methanol, fhO / ethanol, acetonitrile, and mixtures thereof to obtain the co-crystal. It is understood that for the preparation of a co-crystal of ABX464, 8-chloro-N- (4(trifluoromethoxy)phenyl)quinolin-2-amine can be previously obtained either from a process such as that described in the document WO2010 / 143169 or any other appropriate process. Co-crystal of ΆΒΧ 464, pharmaceutically acceptable salts of ABX 464 and pharmaceutical compositions according to the invention for use as medicaments According to another aspect, the present invention further relates to a pharmaceutical composition comprising as active ingredient(s) at least one co-crystal of 8-chloro-N(4-(trifluoromethoxy) phenyl)quinolin-2-amine as defined herein and / or at least one of the pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention and at least one pharmaceutically acceptable excipient. According to another aspect, the present invention further relates to a pharmaceutical composition, wherein the pharmaceutical composition comprises at least one of the co-crystals defined in the present invention and / or at least one of the pharmaceutically acceptable salts of 8-chloro -N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein, as the sole pharmaceutically active ingredient(s). (s). The pharmaceutically acceptable compositions of the present invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as powders, ointments or drops), orally, as an oral or nasal spray, or similar, depending on the severity of the infection being treated. The term parenteral, as used herein, includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. In certain embodiments, the cocrystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy) phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof, of the invention, may be administered orally or parenterally at dosage levels of the active ingredient of ABX464 contained in the co-crystal or salt of approximately 0.01 mg / kg to about 50 mg / kg and preferably from about 1 mg / kg to about 25 mg / kg, of the body weight of the subject per day, one or more times a day, to obtain the desired therapeutic effect. Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions such as aqueous solutions, suspensions such as aqueous suspensions, syrups and elixirs. In addition to the co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy) )phenyl)quinolin-2-amine including a rczonn / zznz / E / YiAi solvate and / or a hydrate thereof as defined herein, liquid dosage forms may contain inert diluents commonly used in the art such as , for example, water or other solvents, solubilizing and emulsifying agents such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, peanut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters, and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavorings, coloring and perfuming agents. When aqueous suspensions are required for oral use, the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8- chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein, may be combined with emulsifying and suspending agents. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a parenterally acceptable non-toxic diluent or solvent, for example, as a solution in 1,3-butanediol. Acceptable vehicles and solvents that may be used include water, Ringer's solution, U.S.P. and an isotonic sodium chloride solution. Furthermore, sterile fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. Additionally, fatty acids such as oleic acid are used in the preparation of injectable substances. Injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium before use. The compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the salts pharmaceutically acceptable 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or hydrate thereof as defined herein with suitable non-irritating excipients or vehicles such as cocoa butter, polyethylene glycol, or a suppository wax that is solid at room temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active ABX464. Solid dosage forms for oral administration include capsules, tablets, pills, powders, lozenges, gums, and granules. In such solid dosage forms, the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention is mixed with at least one pharmaceutically acceptable inert excipient or vehicle such as sodium citrate or dicalcium phosphate and / or a) fillers or diluents such as starches such as corn starch, lactose, sucrose, glucose, mannitol and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose and gum arabic , c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) solution retarding agents such as paraffin, f ) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. If desired, certain sweetening, flavoring or coloring agents can also be added. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules, using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and coatings such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. They may optionally contain opacifying agents and may also be of a composition that releases the active ingredient(s) only, or preferably, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of inclusion compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type can also be used as fillers in soft and hard filled gelatin capsules, using excipients such as lactose or milk sugar as well as eight high molecular weight polyethylene glycols and the like. The co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy) Phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention may also be in microencapsulated form with one or more excipients as indicated above. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and coatings such as enteric coatings, release controlling coatings and other coatings well known in the art of pharmaceutical formulation. In such solid dosage forms, the cocrystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4 (trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, may be mixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, for example, tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and may also be of a composition that releases the active ingredient(s) only, or preferably, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of inclusion compositions that can be used include polymeric substances and waxes. The pharmaceutically acceptable compositions of the present invention can also be administered topically, especially when the target of treatment includes areas or organs easily accessible by topical application, including diseases of the eyes, skin or lower intestinal tract. Suitable topical formulations are easily prepared for each of these areas or organs. Topical application to the lower rczonn / zznz / E / YiAi intestinal tract can be made in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical transdermal patches can also be used. For topical applications, the provided pharmaceutically acceptable compositions may be formulated into a suitable ointment containing the active component suspended or dissolved in one or more vehicles. The vehicles for topical administration of the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N- (4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention includes, but is not limited to, mineral oil, liquid petroleum jelly, white petroleum jelly, propylene glycol, polyoxyethylene, Composite polyoxypropylene, emulsifying wax and water. Alternatively, the provided pharmaceutically acceptable compositions may be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. Furthermore, the present invention contemplates the use of transdermal patches, which have the added advantage of providing a controlled delivery of a compound to the body. Such dosage forms may be prepared by dissolving or dispensing the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined herein and / or the pharmaceutically acceptable salts of 8-chloro. -N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein in the appropriate medium. Absorption enhancers can also be used to increase the flow of the compound through the skin. The rate can be controlled either by providing a rate control membrane or by dispersing the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine co-crystal as defined in the present invention and / or pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein in a polymeric matrix or gel. Dosage forms for topical or transdermal administration of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined herein and / or a pharmaceutically acceptable salt of 8 -chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein includes ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy) phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, is mixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservatives or buffers that may be required. Ophthalmic formulation, ear drops and eye drops are also contemplated within the scope of the present invention. In fact, for ophthalmic use, the provided pharmaceutically acceptable compositions can be formulated as micronized suspensions in pH-adjusted isotonic sterile saline or, preferably, as solutions in pH-adjusted isotonic sterile saline, with or without a preservative such as sodium chloride. benzylalkonium. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petroleum jelly. The pharmaceutically acceptable compositions of the present invention may also be administered by nasal spray or inhalation. Such compositions are prepared according to techniques well known in the field of pharmaceutical formulation and may be prepared as solutions in a saline solution, employing benzyl alcohol or other suitable preservatives, absorption promoters to improve bioavailability, fluorocarbons and / or other agents. conventional solubilizers or dispersants. Even more preferably, the pharmaceutically acceptable compositions of the present invention are formulated for oral administration. Such formulations can be administered with or without food. Thus, according to a particular embodiment, the pharmaceutical compositions comprising the co-crystal of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, and at least one pharmaceutically acceptable excipient, are in particular in the form of tablets, capsules, pills, lozenges, chewing gums, powders, granules, suppositories, emulsions, microemulsions, solutions such as aqueous solutions, suspensions such as aqueous suspensions, syrups, elixirs, ointments, drops, pastes, creams, lotions , gels, sprays, inhalants or patches. rczonn / zznz / E / YiAi In some embodiments, the pharmaceutically acceptable compositions of the present invention are administered without food. In other embodiments, the pharmaceutically acceptable compositions of the present invention are administered with food. The amount of the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4-( trifluoromethoxy)phenyl)quinolin-2-amine that include a solvate and / or a hydrate thereof as defined in the present invention that can be combined with the excipient or carrier materials to produce a composition in a single dosage form, will vary depending on the guest treated, the particular mode of administration. Among the pharmaceutical compositions according to the invention there can be mentioned, more especially, those that are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or dragees, granules, sublingual tablets, capsules, lozenges, suppositories, creams, ointments , dermal gels, injectable preparations, drinkable suspensions and chewing gums. According to a particular embodiment, a pharmaceutical composition according to the invention is an oral pharmaceutical composition. The oral pharmaceutical composition of the present invention may be in the form of capsules, tablets or sachets comprising the composition in powder form. A therapeutically effective oral dosage for the formulations of the invention is determined by standard clinical techniques according to the judgment of a physician. According to one embodiment, when the co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N-(4 (trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention are formulated into capsules, tablets, suspensions, solutions or syrups using conventional methods, protected in blisters. Another advantage conferred by the use of blisters is that the capsules or tablets are also protected from oxygen and other contaminants. The capsules may be soft gelatin capsules or hard gelatin capsules. When the capsules are soft gelatin capsules or hard gelatin capsules, they may advantageously comprise liquid excipients in particular: - lipophilic liquid carriers, - semi-solid lipophilic carriers / viscosity modifiers for lipophilic liquid carriers, solubilizing agents, surfactants, emulsifiers and moisture enhancers. adsorption, Among these excipients the following can be mentioned as shown below: rczonn / zznz / E / YiAi - Special refined oils such as: - Peanut oil - Castor oil - Cotton oil - Corn oil - Olive oil - Sesame oil - Soybean oil -Sunflower oil Medium chain triglycerides and related esters such as: - Caprylic / capric triglycerides (Akomed E, Akomed R, Miglyol 810 and Captex 355) - Medium chain triglycerides (Labrafac CC) Caprylic / Capric Acid Propylene Glycol Diester (Labrafac PG) - Propylene Glycol Monolaurate (Lauroglycol FCC) - Fractionated Coconut Oil (Miglyol 812) Caprylic / capric / diglyceryl succinate (Miglyol 829) Medium chain diesters of propylene glycols (Miglyol 840) - Partial ester of diglycerides with natural fatty acids (Softisan 645). Solubilizing agents, surfactants, emulsifiers and adsorption enhancers such as: - Propylene glycol monocaprylate (Capryol 90) Polyglycolized glycerides (Gelucire 44 / 14 and 50 / 13) Polyoxyl-40 hydrogenated castor oil (Cremophor RH 40) Glycerol monostearate / di-triglycerides + glycerin (Imwitor 191) - Glyceryl monocaprylate (Imwitor 308*) - Glyceryl cocoate / citrate / lactate (Imwitor 380) - Glyceryl mono-dicaprilat / caprate (Imwitor 742) - Diglyceryl succinate and isosteryl (Imwitor 780 K) - Glyceryl cocoate (Imwitor 928) - Glyceryl caprylate (Imwitor 988) - Oleoyl macrogol-8 glycerides (Labrafil M 1944 CS) - Linoleoyl macrogolglycerides (Labrafil M 2125 CS) - Caprylic / capric glycerides PEG-8 (Labrasol) - Lauric acid - Propylene glycol laurate (Lauroglycol 90) - Oleic acid - Polyethylene glycol - Propylene glycol - Polyglycerol dioleate (Plurol Oleique CC 497) rczonn / zznz / E / YiAi Polyoxyethylene-polyoxypropylene copolymer (Poloxamers 124 and 188) - Partial glycerides of hydroxylated unsaturated fatty acids (Softigen 701) - PEG-6 caprylic / capric glycerides (Softigen 767) - Polyoxyethylene glyceryl trioleate (Tagat TO) Polyoxyethylene sorbitan monooleate (20) (Tween 80). In some embodiments, the present invention provides a tablet or capsule comprising the cocrystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention and / or pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein, and at least one pharmaceutically acceptable excipient. In some particular embodiments, the present invention provides a capsule comprising the co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutical salts acceptable 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein, and at least one pharmaceutically acceptable excipient, or a tablet comprising granules formed by the co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention and / or the pharmaceutically acceptable salts of 8-chloro-N- (4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention and at least one intragranular excipient, such granules being compressed together with at least one excipient extragranular. When the pharmaceutical composition according to the invention is a tablet, the tablet may be coated or uncoated. Preferably, the tablet is coated using any appropriate film coating agent well known in the art. Provided herein in particular is an oral dosage form comprising at least one co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention and / or at least one of the pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined above and at least one precipitation inhibitor as is defined above. Also provided herein are coated oral dosage forms, in particular intended for delayed release dosage forms, comprising at least one co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2- amine as defined above and / or at least one of the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined previously. Delayed release dosage forms are a particular modified dosage form that allows the release of the active ingredient from the dosage form after a certain time after administration, and for example once the active ingredient reaches the intestinal tract. The term modified release dosage form means that the dosage form allows for the release into the body of a specific amount over a specific period of time of an active ingredient, specifically, a specific pharmacokinetic profile. The term modified release covers all types of releases that are modified compared to an immediate release. In other words, the term controlled release is equivalent to modified release and encompasses both prolonged releases, delayed releases and pulsed releases. The oral dosage form may take the form of multiparticle drug delivery systems or multilayer compression-coated tablets. The coating can be chosen from polymers that allow the salt or co-crystal to be rapidly solubilized once the dosage form reaches the biological target, and more particularly reaches the intestinal tract, and the polymer is solubilized. Therefore, the present invention further provides the use of at least one co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined above and / or at least one of the salts pharmaceutically acceptable 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine including a solvate and / or a hydrate thereof as defined above to manufacture a delayed release oral dosage form. The useful dosage may vary depending on the nature and severity of the disorder, the route of administration, and the age and weight of the patient. According to one embodiment, a pharmaceutical composition according to the invention is such that a dose of 1 mg to 1 g per day, particularly 10 mg to 150 mg per day of the active ingredient of ABX464 is administered to a subject in need thereof. in one or more doses a day. The excipients can be any conventionally used excipient, including intragranular excipients, 100 and / or extragranular excipients. Excipients can be selected from fillers, slip agents, binders, antioxidants, disintegrants, lubricants, surfactants, precipitation inhibitors, film coating agents and mixtures thereof. Fillers that can be used in accordance with the invention include, but are not limited to, lactose (anhydrous), lactose monohydrate, spray dried lactose; compressible sugar, dextrose, dextrates; starches (including starches of any origin, such as corn, potato, rice, wheat, which may be fully pregelatinized and partially gelatinized); cellulose; microcrystalline cellulose; inorganic salts such as calcium phosphate, tribasic calcium and calcium sulfate; and polyols such as mannitol, sorbitol and xylitol. In some embodiments, the filler may be in an amount of 10% to 85% by weight with respect to the total weight of the composition. Lubricants that can be used according to the invention include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oils, mineral oil, polyethylene glycols, talc, glyceryl behenate, monostearate glyceryl, glyceryl palmitostearate, rczonn / zznz / E / YiAi 101 leucine and magnesium lauryl sulfate. In some embodiments, the lubricant may be in an amount of 0.3% to 2% by weight with respect to the total weight of the composition. Disintegrants that can be used in accordance with the invention include, but are not limited to, croscarmellose sodium, sodium starch glycolate, starches (including starches from any source, such as corn, potato, rice, wheat, fully pregelatinized and partially gelatinized), crospovidone, alginates such as calcium alginate and sodium alginate, alginic acid and magnesium aluminum silicate. In some embodiments, the disintegrant may be in an amount of 30% to 60% by weight with respect to the total weight of the composition. Surfactants that can be used as an additive in the present invention include, among others, sodium lauryl sulfate, tocopherol, lecithin, lauryl sulfate, vitamin E, egg yolk phosphatides, docusate sodium, capriol, labrafil, labrasol, lauroglycol, solutol (Macrogol-15 hydroxystearate), and mixtures thereof. In some embodiments, the surfactant may be in an amount of 1% to 3% by weight relative to the total weight of the composition. The slip agents that can be used from rczonn / zznz / E / YiAi 102 according to the invention include, but are not limited to, colloidal silicon dioxide. In some embodiments, the slip agent may be in an amount of 0.3% to 2% by weight with respect to the total weight of the composition. In some embodiments, the binder may be in an amount of 5% to 20% by weight with respect to the total weight of the composition. The pharmaceutical compositions according to the present invention may be in modified, sustained, controlled, delayed or immediate release form. According to another aspect, the present invention also relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro -N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for its use as a medicine. According to another aspect, the present invention also relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro -N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine which rczonn / zznz / E / YiAi 103 includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use in the prevention and / or treatment of inflammatory diseases such as inflammatory disease intestinal, rheumatoid arthritis, pulmonary arterial hypertension, NASH (non-alcoholic steatohepatitis) and multiple sclerosis, diseases caused by viruses and / or cancer or dysplasia. According to another aspect, the present invention also relates to the use of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, of a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or of a pharmaceutical composition as defined in the present invention for the manufacture of a medicine. According to another aspect, the present invention also relates to the use of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, of a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or of a pharmaceutical composition as defined in the present invention for the manufacture of 104 a medicine for the prevention and / or treatment of inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH (non-alcoholic steatohepatitis) and multiple sclerosis, diseases caused by viruses and / or cancer or dysplasia. According to another aspect, the present invention also relates to a therapeutic method for the treatment and / or prevention of inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH (non-alcoholic steatohepatitis) and multiple sclerosis, diseases caused by viruses and / or cancer or dysplasia comprising administering to a patient in need thereof a composition comprising a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention and / or a pharmaceutically acceptable salt of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention. According to another aspect, the present invention also relates to a therapeutic method for the treatment and / or prevention of inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH (non-inflammatory steatohepatitis). 105 alcoholic) and multiple sclerosis, diseases caused by viruses and / or cancer or dysplasia comprising administering to a patient in need a therapeutically effective amount of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl )quinolin-2-amine as defined in the present invention and / or a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate of the same as defined in the present invention. A method is provided for administering an ABX464 cocrystal to a subject in need thereof, comprising: - providing an oral pharmaceutical composition comprising: a co-crystal of ABX464 and / or a pharmaceutically acceptable salt of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, and at least one pharmaceutically acceptable excipient; and orally administering the pharmaceutical composition in a therapeutically effective amount to a subject in need thereof. An ABX464 co-crystal as defined in the present invention may be administered alone or in combination with other therapeutic agents that may act synergistically with such ABX464 co-crystal as defined in the present invention. 106 For example, another therapeutic agent may be a pharmaceutically acceptable salt of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof as defined herein. . By analogy, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein may be administered alone or in combination with other therapeutic agents that can act synergistically with such pharmaceutically acceptable salt of ABX464 including a solvate and / or a hydrate thereof as defined in the present invention. For example, another therapeutic agent may be a co-crystal of ABX464 as defined in the present invention. inflammatory diseases Therefore, the invention also relates to a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N -(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use in the treatment and / or prevention of an inflammatory disease. rczonn / zznz / E / YiAi 107 According to the invention, inflammation is a protective response of the immune system against tissue damage and infection. However, the inflammatory response, in some circumstances, can harm the body. In the acute phase, inflammation is characterized by pain, heat, redness, swelling, and loss of function. Inflammation can result from infection, irritation, or injury. Thus, an inflammatory disease refers to a group of diseases and / or disorders that are caused by excessive or dysregulated inflammation. Without limitation, inflammatory diseases include: an inflammatory disease associated with an autoimmune disease, an inflammatory disease of the central nervous system (CNS), an inflammatory joint disease, an inflammatory disease of the digestive tract, an inflammatory skin disease and other inflammatory diseases related to epithelial cells such as bronchitis, inflammation associated with cancer, such as colon carcinoma, inflammation associated with irritation and inflammation associated with injury. According to the present invention, the inflammatory disease, disorder or condition is selected from: (a) an inflammatory disease, disorder or condition in the pancreas selected from type 1 diabetes, rczonn / zznz / E / YiAi 108 type 2 diabetes, acute and chronic pancreatitis; (b) an inflammatory disease, disorder or condition in the kidney selected from glomerulosclerosis, glomerulonephritis, nephritis, acute kidney injury, Berger's disease, Goodpasture syndrome, Wegener's granulomatosis and acute or chronic kidney transplant rejection; (c) an inflammatory disease, disorder or condition in the liver selected from nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), cholestatic liver disease, sclerosing cholangitis and acute or chronic liver transplant rejection; (d) an inflammatory disease, disorder or condition in the lung or heart selected from chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, pulmonary arterial hypertension, sarcoidosis, myocarditis, pericarditis and acute or chronic lung transplant rejection or heart; (e) an inflammatory disease, disorder or condition in the skin selected from contact dermatitis, atopic dermatitis, urticaria, chronic dermatitis, psoriasis, eczema, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, acne, keloid scar and rczonn / zznz / E / YiAi 109 other inflammatory or allergic skin conditions; (f) an inflammatory disease, disorder or condition, in the vessel / blood selected from Behcet's disease, vasculitis, sepsis, tumor angiogenesis, atherosclerosis, proliferative vascular disease and restenosis; (g) an inflammatory disease, disorder or condition of the eye selected from conjunctivitis, scleritis, episcleritis, panuveitis, choroiditis, chorioretinitis, neuroretinitis, uveitis, orbital inflammatory disease and optic neuritis; (h) an inflammatory disease, disorder or condition in the central or peripheral nervous system selected from non-viral and viral encephalitis and meningitis, depression, neuropathic pain, chronic pain, traumatic brain injury, including stroke, Alzheimer's disease, Parkinson's disease , myelitis, Charcot-Marie-Tooth disease type 1 (including CMT1A and CMT1B), multiple sclerosis, amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease, demyelinating polyneuropathy and peripheral neuropathy; (i) an autoimmune disease, disorder or condition selected from lupus, including of the skin and kidney, Guillain-Barré syndrome, myasthenia gravis, Hashimoto's thyroiditis, idiopathic purpura, aplastic anemia, Graves' disease and rczonn / zznz / E / YiAi myocarditis; (j) an inflammatory disease, disorder or condition in the intestine selected from intestinal failure, ulcerative colitis (UC) and Crohn's disease, (k) an inflammatory disease, disorder or condition, in the reproductive system selected from endometriosis, uterine fibroid, prostate dysplasia or growth and cervical dysplasia; and (1) an inflammatory disease, disorder, or condition in the bones and / or joints selected from rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, periodontitis, and arthritis of the hands, feet, ankles, knees, hips, shoulders, elbows, or spine vertebral and / or demineralization. In a particular embodiment, the inflammatory disease can be selected from the list consisting of: an inflammatory disease associated with an autoimmune disease, an inflammatory disease of the central nervous system (CNS), an inflammatory joint disease, an inflammatory disease of the digestive tract , an inflammatory skin disease and other inflammatory diseases related to epithelial cells, inflammation associated with cancer, inflammation associated with irritation, and inflammation associated with injury. In particular, a disease rczonn / zznz / E / YiAi is selected 111 inflammatory list consisting of: inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren's syndrome, bronchitis, asthma , pulmonary arterial hypertension, NASH and inflammation associated with colon carcinoma. More specifically, an inflammatory disease is selected from the list consisting of: inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, bronchitis, pulmonary arterial hypertension, NASH and inflammation associated with colon carcinoma. More particularly, an inflammatory disease is selected from the list consisting of: inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, pulmonary arterial hypertension, NASH and psoriasis. Preferably, an inflammatory disease according to the invention includes: inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, pulmonary arterial hypertension, NASH and multiple sclerosis. Even more preferably, a rczonn / zznz / E / YiAi disease 112 inflammatory according to the invention includes: inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH and multiple sclerosis. An inflammatory disease can also encompass Alzheimer's disease, Parkinson's disease, asthma, atherosclerosis and dermatitis. As dermatitis, eczema can be mentioned. In view of the above, the invention relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use in the treatment and / or prevention of an inflammatory disease, which encompasses inflammation as such, and inflammation associated with an inflammatory disease. Therefore, the invention also relates to the use of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro- N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as 113 is defined in the present invention to treat and / or prevent an inflammatory disease, encompassing inflammation as such, and inflammation associated with an inflammatory disease. The invention also relates to the use of a cocrystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined herein, or a pharmaceutically acceptable salt of 8-chloro-N-(4 (trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, for the preparation of a composition, such as a medicament, for treating and / or preventing inflammation , which encompasses inflammation as such, and inflammation associated with an inflammatory disease. The invention also relates to a method for treating and / or preventing an inflammatory disease, including inflammation as such, and inflammation associated with such an inflammatory disease, and comprising a step of administering an 8-chloro co-crystal. -N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention to a patient in need thereof. rczonn / zznz / E / YiAi 114 In some embodiments, a method of the present invention or a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use as defined defined above, to treat an inflammatory disease, disorder or condition further comprises measuring and / or monitoring the presence and / or level of a biomarker in a patient, for example, in a sample of blood, plasma, tissue, saliva and / or serum. In some embodiments, a biomarker measured and / or monitored in a method of the present invention is miR-124. In some embodiments, a method of the present invention or a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use as defined defined above, to treat an inflammatory disease, disorder or condition, further comprises measuring and / or monitoring the presence and / or expression level of miR-124 in a patient, 115 for example, in a sample of blood, plasma, tissue, saliva and / or serum, before administration a co-crystal of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in The present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention as described herein. In some embodiments, a method of the present invention or a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use as defined defined above, to treat an inflammatory disease, disorder or condition further comprises measuring and / or monitoring the presence and / or expression level of miR-124 in a patient during the course of treatment with an 8-chloro co-crystal -N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof such as 116 as defined in the present invention, or a pharmaceutical composition as defined in the present invention thereof as described herein. In some embodiments, a method of the present invention for treating an inflammatory disease, disorder or condition, or a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined herein invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein, or a pharmaceutical composition as defined herein. defined in the present invention for use as defined above, it further comprises selecting a patient for treatment with a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention as described herein, measuring and / or monitoring a presence and / or expression level of miR-124 in the patient. A provided co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or a pharmaceutically acceptable salt 117 provided of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention may be administered alone or in combination with one or more therapeutic compounds, the possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds that are staggered or administered independently of each other, or the combined administration of fixed combinations and one or more other therapeutic compounds. A compound of the present invention may further be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention or a combination thereof. Long-term therapy is equally possible as adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's condition after tumor regression, or even chemopreventive therapy, for example in patients at risk. These additional agents may be administered separately from a provided co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined herein, or from a pharmaceutically acceptable salt. 118 provided of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, as part of a multiple dosage regimen. Alternatively, these agents may be part of a single dosage form, mixed with a co-crystal provided with 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention, or with a pharmaceutically acceptable salt provided with 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein in a single composition. If administered as part of a multiple dosing regimen, the two active agents may be administered simultaneously, sequentially, or within a period of time of each other, typically within five hours of each other. As used herein, the term combination, combined and related terms refer to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a provided co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or a provided pharmaceutically acceptable salt of 8-chloro-N-(4 (trifluoromethoxy)phenyl)quinolin-2-amine including a rczonn / zznz / E / YiAi 119 solvate and / or a hydrate thereof as defined in the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a provided co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or a salt pharmaceutically acceptable provided of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein, an additional therapeutic agent and a carrier, pharmaceutically acceptable adjuvant or vehicle. In some embodiments, the co-crystal of 8-chloro-N(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or the pharmaceutically acceptable salt of 8-chloro-N-(4- (trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein may be administered with one or more additional therapeutic agents. Such additional therapeutic agents may be small molecules or recombinant biological agents and include, for example, acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and 120 celecoxib, colchicine (Colcrys®), corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone and similar, probenecid, allopurinol, febuxostat (Uloric®), sulfasalazine (Azulfidine®), antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen® ), methotrexate (Rheumatrex®), gold salts such as gold thioglucose (Solganal®), gold thiomalate (Myochrysine®) and auranofin (Ridaura®), D-penicillamine (Depen® or Cuprimine®), azathioprine (Imuran®) , cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®, Neoral®), tacrolimus, sirolimus, mycophenolate, leflunomide (Arava®), and anti-TNF agents such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Simponi®), certolizumab pegol (Cimzia®) and adalimumab (Humira®), anti-IL-1 agents such as anakinra (Kineret®) and rilonacept (Arcalyst®), anti-T cell antibodies such as Thymoglobulin, IV immunoglobulins (IVIg), canakinumab (Ilaris®), anti-Jak inhibitors such as tofacitinib, antibodies such as rituximab (Rituxan®), anti-T cell agents such as abatacept (Orencia®), anti-IL-6 agents such as tocilizumab (Actemra®), diclofenac, cortisone, acid hyaluronic acid (Synvisc® or Hyalgan®), monoclonal antibodies such as tanezumab, anticoagulants such as heparin (Calcinparine® or Liquaemin®) and warfarin (Coumadin®), antidiarrheals such as diphenoxylate (Lomotil®) and loperamide (Imodium®), bile acid binding agents such as cholestyramine, alosetron rczonn / zznz / E / YiAi 121 (Lotronex®), lubiprostone (Amitiza®), laxatives such as milk of magnesia, polyethylene glycol (MiraLax®), Dulcolax®, Correctol® and Senokot®, anticholinergics or antispasmodics such as dicyclomine (Bentyl®), Singulair®, beta-2 agonists such as albuterol (Ventolín® HFA, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®) and formoterol ( Foradil®), anticholinergic agents such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), inhaled corticosteroids such as beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex ®), budesonide (Pulmocort®) and flunisolide (Aerobid®), Afviar®, Symbicort®, Dulera®,cromolin sodium (Intal®), methylxanthines such as theophylline (Theo-Dur®, Theolair®, Slo-bid®, Uniphyl® , Theo-24®) and aminophylline, IgE antibodies such as omalizumab (Xolair®), nucleoside reverse transcriptase inhibitors such as zidovudine (Retrovir®), abacavir (Ziagen®), abacavir / lamivudine (Epzicom®), abacavir / lamivudine / zidovudine (Trizivir®), didanosine (Videx®), emtricitabine (Emtriva®), lamivudine (Epivir®), lamivudine / zidovudine (Combivir®), stavudine (Zerit®) and zalcitabine (Hivid®), reverse transcriptase inhibitors non-nucleosides such as delavirdine (Rescriptor®), efavirenz (Sustiva®), nevairapine (Viramune®), and etravirine (Intelence®), 122 nucleotide reverse transcriptase inhibitors such as tenofovir (Viread®), protease inhibitors such as amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Lexiva®), indinavir (Crixivan®), lopinavir and ritonavir (Kaletra®), nelfinavir (Viracept®), ritonavir (Norvir®), saquinavir (Fortovase® or Invirase®) and tipranavir (Aptivus®), entry inhibitors such as enfuvirtide (Fuzeon®) and maraviroc (Selzentry®) , integrase inhibitors such as raltegravir (Isentress®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), bortezomib (Velcade®) and dexamethasone (Decadron ®) in combination with lenalidomide (Revlimid®), anti-IL36 agents such as BI655130 , dihydroorotate dehydrogenase inhibitors such as IMU-838, anti-OX40 agents such as KHK-4083, microbiome agents such as RBX2660, SER-287, narrow-spectrum kinase inhibitors such as TOP-1288, anti-CD40 agents such as BI-655064 and FFP-104, guanylate cyclase agonists such as dolcanatide, sphingosine kinase inhibitors such as opaganib, anti-IL-12 / IL-23 agents such as AK-101, ubiquitin protein ligase complex inhibitors such as BBT-401, ubiquitin receptor modulators sphingosine such as BMS-986166, P38MAPK / PDE4 inhibitors, HIF-PH inhibitors such as FG-6874, a HIF-Ια stabilizer such as GB-004, MAP3K8 protein inhibitors such as GS-4875, LAG-3 antibodies such as GSK2831781 , RIP2 kinase inhibitors such as GSK-2983559, rczonn / zznz / E / YiAi 123 farnesoid ICAM-1 such as alicaforsen sodium, anti-IL23 agents such as guselkumab, brazikumab and mirkizumab, anti-IL-15 agents such as AMG-714, TYK-2 inhibitors such as BMS-986165, NK cell activators such as CNDO-201, RIP-1 kinase inhibitors such as GSK-2982772, anti-NKGD2 agents such as JNJ-4500, CXCL-10 antibodies such as JT-02, IL-22 receptor agonists such as RG-7880, GATA-3 antagonists such as SB-012, and stimulating factor receptor inhibitors of colonies 1 such as edicotinib or any combination(s) thereof. Diseases caused by viruses A co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin- 2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, may be useful in the treatment or prevention of various diseases caused by viruses, in particular by retroviruses and more particularly by HIV, and more particularly for use to decrease the viral load in a patient infected by a virus, in 124 particularly HIV, or a condition related to the virus, with a long-lasting effect and absence of resistance. Examples of viruses considered by the invention include enveloped and naked viruses, including DNA viruses, RNA viruses and retroviruses, including dsDNA viruses, ssDNA viruses, dsRNA viruses, (+)ssRNA viruses, (+)ssRNA viruses, )ssRNA, ssRNA-RT viruses and dsDNA-RT viruses. Viruses considered more particularly are RNA viruses and retroviruses, including lentiviruses, and preferably HIV. Accordingly, the most particularly considered virus-related conditions are associated with an RNA virus or a retrovirus, and preferably with HIV. HIV can include HIV-I, HIV-2, and all subtypes thereof, including HIV-I strains belonging to HIV-I subtype B, HIV-I subtype C, and HIV-I recombinants. Examples include HIV-I strains selected from Ad8, AdaM, Isolate B, Isolate C, CRF01, CRF02 and CRF06. According to a preferred embodiment, the virus-related condition is AIDS. Within the retroviral family, three subfamilies can be distinguished: oncoviruses, lentiviruses and spumaviruses. HIV belongs to lentiviruses. According to a particular embodiment, retroviruses include HIV virus (HIV1 and HIV2), visna / maedi virus or MVV / visna, equine infectious anemia virus or EIAV, rczonn / zznz / E / YiAi virus 125 caprine arthritis encephalitis or CAEV, simian immunodeficiency virus or SIV, avian leukemia virus or ALV, murine leukemia virus also called Moloney virus or MULV, Abelson leukemia virus, tumor virus murine mammary gland, Mason-Pfizer monkey virus or MPMV, feline leukemia virus or FELV, human leukemia virus HTLV-I, human leukemia virus HTLV-II, simian leukemia virus or STLV, viruses bovine leukemia virus or BLV, primate type D oncovirus, type B oncovirus, Rous sarcoma virus or RSV, simian foamy virus or SFV or simian and chimpanzee virus, human foamy virus and feline immunodeficiency virus, the human foamy virus or HFV, bovine syncytial virus or BSV, feline syncytial virus FSV, feline immunodeficiency virus, avian leukosis virus, Walleye dermal sarcoma virus, T-cell lymphoma, acute ATL, lymphomatous ATL, chronic ATL , latent ATL, neurological diseases, tropical spastic paraparesis or myelopathy associated with HTLV, inflammatory and autoimmune diseases such as uveitis, dermatitis, pneumonitis, rheumatoid arthritis and polymyositis, hematological and dermatological diseases, lung diseases, brain diseases and / or immunodeficiency. As described herein, the term oncovirus may include alpharetrovirus (e.g., avian leukosis virus and Rous sarcoma virus); 126 betaretroviruses (e.g. mouse mammary tumor virus); gammaretrovirus (for example, murine leukemia virus and feline leukemia virus); deltarretrovirus (for example, bovine leukemia virus and human T-lymphotropic virus); and epsilonretrovirus (e.g., Walleye dermal sarcoma virus). More generally, the retroviruses described herein may be, for example, visna / maedi virus or MVV / visna, equine infectious anemia virus or EIAV, caprine arthritis and encephalitis virus or CAEV, caprine arthritis and encephalitis virus or CAEV, simian immunodeficiency virus or SIV, avian leukemia virus or ALV, murine leukemia virus also called Moloney virus or MULV, Abelson leukemia virus, murine mammary tumor virus, Mason-Pfizer monkey virus or MPMV, feline leukemia virus or FELV, human leukemia virus HTLV-I, human leukemia virus HTLV-II, monkey leukemia virus or STLV, bovine leukemia virus or BLV, primate oncoviruses type D, type B oncoviruses, Rous sarcoma virus or RSV, and / or simian foamy virus or SFV or simian and chimpanzee virus, human foamy virus and feline immunodeficiency virus, human foamy virus (or HFV), bovine syncytial virus (or BSV), feline syncytial virus (FSV) and feline immunodeficiency virus. More particularly, HTLV-I causes rczonn / zznz / E / YiAi cell lymphoma 127 T (ATL for adult T-cell leukemia / lymphoma, including different forms of ATL such as acute ATL, lymphomatous ATL, chronic ATL, and smoldering ATL), neurological disease, tropical spastic paraparesis (TSP) (also known as HTLV-associated myelopathy ( HAM) or chronic progressive myelopathy), and various inflammatory and autoimmune diseases such as uveitis, dermatitis, pneumonitis, rheumatoid arthritis, and; HTLV-II may play a role in certain neurological, hematological, and dermatological diseases; HIV (HIV1 and HIV2) causes AIDS; the visna virus causes lung and brain diseases in sheep; the feline immunodeficiency virus causes immunodeficiency in the cat; Rous sarcoma virus and mouse mammary tumor virus cause tumor growth and cancer. The invention also relates to a method for the treatment and / or prevention of diseases caused by viruses, in particular by retroviruses and more particularly by HIV, and comprising a step of administering a co-crystal of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention to a patient in need thereof. rczonn / zznz / E / YiAi 128 Additionally, the purpose of the present invention is to reduce the viral load in a patient infected by a virus, in particular HIV, or a condition related to the virus, with a lasting effect and absence of resistance, through the use of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention. In one embodiment, the present invention relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N- (4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use to treat or prevent a retroviral infection or a retrovirus-related condition, in particular an HIV infection or an HIV-related condition in a patient, for which a previous antiretroviral treatment has been declared ineffective or decreased in effectiveness. In another embodiment, the present invention relates to rczonn / zznz / E / YiAi 129 to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl) quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use to treat or prevent a retroviral infection or condition related to a retrovirus, in particular an HIV infection or an HIV-related condition in a patient, in which the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant strain of HIV . Furthermore, the invention further relates to new doses and regimens of such co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or such pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention and its use in the treatment or prevention of viral infection, and in particular HIV, or a condition related to the virus, more particularly where use maintains a low viral load after completion of treatment. Thus, according to one embodiment, the invention relates to a co-crystal of 8-chloro-N-(4 rczonn / zznz / E / YiAi 130 (trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use to treat or prevent a virus infection or a virus-related condition in a patient, in particular a virus infection HIV or an HIV-related condition, in which: a low or undetectable viral load is maintained; and / or the CD4+ cell count is stable or increased; after completion of treatment. According to another embodiment, the invention relates to a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N- (4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use in the treatment or prevention of a virus infection or virus-related condition in the patient, in particular an HIV infection or an HIV-related condition, for which an ineffectiveness of previous antiretroviral treatment, or a decrease in the effectiveness of a treatment rczonn / zznz / E / YiAi 131 antiretroviral or previous antiretroviral has been declared. According to yet another embodiment, the invention relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined herein, a pharmaceutically acceptable salt of 8-chloro-N- (4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use in the treatment or prevention of a virus infection or a virus-related condition in the patient, in particular an HIV infection or an HIV-related condition, in which the patient is infected by a drug-resistant strain. Within the framework of the present invention, the co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or the pharmaceutically acceptable salt of 8-chloro -N- (4(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein may be administered in combination with another antiretroviral agent. According to one embodiment, an ART (Antiretroviral Therapy) or HAART (Highly Active Antiretroviral Therapy) may be implemented using one or more of the following antiretroviral compounds: 132 (i) nucleoside / nucleotide reverse transcriptase inhibitors, also called nucleoside analogues, such as abacavir, emtricitabine and tenofovir; (ii) non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, etravirine, and nevirapine; (iii) protease inhibitors (PIs), such as atazanavir, darunavir, and ritonavir; (iv) entry inhibitors, such as enfuvirtide and maraviroc; (v) integrase inhibitors, such as dolutegravir and raltegravir. Other examples of antiretroviral agents include, but are not limited to: Zidovudine, Lamivudine, Emtricitabine, Didanosine, Stavudine, Abacavir, Zalcitabine, Racivir, Amdoxovir, Apricitabine, Elvucitabine, Efavirenz, Nevirapine, Etravirine, Delavirdine, Rilpvirine, Tenofovir, Fosalvudine, Amprenavir, Tipranavir, Indinavir, Saquinavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Lopinavir, Raltegravir, Elvitegravir, Dolutegravir, Enfuvirtide, Maraviroc, Vicriviroc and combinations thereof. In some embodiments, a co-crystal of 8-chloro-N(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy) )phenyl)quinolin-2-amine including rczonn / zznz / E / YiAi 133 a solvate and / or a hydrate thereof as defined in the present invention, may be administered in combination with one or more additional therapeutic agents selected from nucleoside reverse transcriptase inhibitors such as zidovudine (Retrovir®), abacavir (Ziagen® ), abacavir / lamivudine (Epzicom®), abacavir / lamivudine / zidovudine (Trizivir®), didanosine (Videx®), emtricitabine (Emtriva®), lamivudine (Epivir®), lamivudine / zidovudine (Combivir®), stavudine (Zerit® ) and zalcitabine (Hivid®), non-nucleoside reverse transcriptase inhibitors such as delavirdine (Rescriptor®), efavirenz (Sustiva®), nevairapine (Viramune®), and etravirine (Intelence®), nucleotide reverse transcriptase inhibitors such as tenofovir (Viread®), protease inhibitors such as amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Lexiva®), indinavir (Crixivan®), lopinavir and ritonavir (Kaletra®), nelfinavir ( Viracept®), ritonavir (Norvir®), saquinavir (Fortovase® or Invirase®) and tipranavir (Aptivus®), entry inhibitors such as enfuvirtide (Fuzeon®) and maraviroc (Selzentry®), integrase inhibitors such as raltegravir (Isentress® ) and combinations thereof. A co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin- 2-amine including a solvate and / or a hydrate thereof as defined 134 in the present invention, or a pharmaceutical composition as defined in the present invention, may also be useful in the treatment and / or prevention of diseases caused by a virus belonging to the Coronaviridae family or by an infection caused by Coronaviridae and the conditions related to it, and especially Severe Acute Respiratory Syndrome caused by SARSCoV or SARS-CoV-2 infection, including the strains responsible for COVID19 (also called coronavirus disease 2019) and its mutants. More specifically, SARS-CoV-2, previously known as 2019-nCoV, belongs to the Coronaviridae family and is part of group IV of the Baltimore classification. For reference, the content of the Baltimore classification reported in this document makes additional reference to the taxonomy of viruses as set forth in the International Committee on Taxonomy of Viruses (ICTV) database available at online on March 20, 2020 (email ratification February 2019 and MSL #34) at https: / / talk.ictvonline.org / taxonomy / . This taxonomy is incorporated here in its entirety. Consequently, this classification groups viruses into families (or groups) according to their genome type. The current virus classification, as in 2018, includes seven different groups: rczonn / zznz / E / YiAi 135 - Group I: double-stranded DNA (dsDNA) viruses; - Group II: single-stranded DNA (ssDNA) viruses; - Group III: double-stranded RNA (dsRNA) viruses; - Group IV: stranded or sense RNA viruses (+) ((+)ssRNA); - Group V: stranded or antisense RNA viruses (-) ((-)ssRNA); - Group VI: single-stranded RNA viruses that have DNA intermediate compounds (ssRNA-RT); - Group VII: double-stranded DNA viruses that have RNA intermediate compounds (dsDNA-RT). A co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin- 2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention are further particularly useful for treating and / or preventing severe forms of SARS infections. -CoV-2: anti-inflammatory effects to combat cytokine storm, mucosal efficacy, promotion of tissue repair to avoid long-term post-ventilation sequelae. According to a particular embodiment, a co-crystal of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine such as rczonn / zznz / E / YiAi 136 is defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine that includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, can be used in the early stage of COVID-19. In fact, clinically, SARS-CoV-2 infection can cause cytokine storm syndrome, acute respiratory distress syndrome (ARDS), and multiple organ failure. In particular, cytokine storm (i.e., hyperinflammatory syndrome) has been associated with COVID-19 disease severity (including increased MCP1, IL-Ιβ, TNFα, IL-17, G-CSF, and IL -6). Early treatment and action on viral replication and on the different cytokine pathways make it possible to successfully reduce cytokine storm syndrome and hyperinflammation and prevent ARDS and multiple organ failure. Accordingly, in one embodiment, the present invention relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro -N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition such as rczonn / zznz / E / YiAi 137 is defined in the present invention, for use in a method of treating a group of patients before the onset of a respiratory distress syndrome related to a Coronaviridae infection. Such patients may or may not be hospitalized. Accordingly, in one embodiment, the present invention relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro -N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for its use in a method to treat or prevent the occurrence of a respiratory distress syndrome related to a Coronaviridae infection. According to particular embodiments, a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4 -(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, is for use in a method of treating or prevent a Coronaviridae infection, is to treat or prevent the appearance of a 138 vascular, cardiovascular, neurological or gastrointestinal condition related to a Coronaviridae infection. Advantageously, a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy) )phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, may be considered alone or in combination with any other active agent, in particular any dynamin inhibitor, especially any inhibitor of dynamin-2, for use in the prevention treatment of a Coronavíridae infection. As used herein, a condition related to a Coronaviridae infection, especially a condition related to a severe acute respiratory syndrome coronavirus, such as SARS-CoV2, may be selected from a list comprising or consisting of: severe respiratory distress syndrome, a cardiovascular condition, a vascular condition, a gastrointestinal condition, or a neurological condition. Advantageously, patients who have, or are at risk of having, a condition related to a Coronaviridae infection may also be considered. According to exemplary embodiments, the condition rczonn / zznz / E / YiAi 139 related to a Coronaviridae infection that is particularly considered to include: pulmonary fibrosis, vasculitis, Kawasaki disease and damage or destruction of tissue, in particular damage and destruction of lung tissue. Unless otherwise indicated, all described cocrystals of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, pharmaceutically acceptable salts of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined herein, and pharmaceutical compositions as defined herein, are specifically considered herein for the treatment or prevention of a disease caused by Coronaviridae, which may therefore refer interchangeably to any member of such Coronaviridae family within the meaning of the Baltimore convention, although particular selections of viruses will hereinafter be considered preferred modalities. As used herein, the term Coronaviridae refers to the corresponding family of RNA viruses belonging to group IV of the Baltimore classification, which is itself part of the suborder Coronidovirineae and the Order Nidovirales. The family Coronaviridae includes the subfamilies Letovirinae and Orthocoronavirinae. As used in this document, the term rczonn / zznz / E / YiAi 140 Letovirinae refers to the corresponding family of the Baltimore classification, which includes the genus Alphaletovirus, the subgenus Milecovirus, which includes (but is not limited to) the species Microhyla letovirus 1. As used herein, the term Orthocoronavirinae refers to the corresponding family of the Baltimore classification, which includes the genera Alfacoronavirus, Betacoronavirus, Deltacoronavirus, and Gammacoronavirus. As used herein, the term Alfacorona virus refers to the corresponding family of the Baltimore classification, which includes the subgenera Colacovirus, Decacovirus, Duvinacovirus, Luchacovirus, Minacovirus, Minunacovirus, Myotacovirus, Myctacovirus, Pedacovirus, Rhinacovlrus, Setracovirus and Tegacovirus. Non-exhaustively, this includes the following species: bat coronavirus CDPHE15, bat coronavirus HKU10, Rhinolophus ferrumequinum alfacoronavirus HuB-2013, human coronavirus 229E, rat coronavirus Lucheng Rn, ferret coronavirus, mink coronavirus 1, bat coronavirus Miniopterus 1, Miniopterus bat coronavirus HKU8, Myotis ricketti alfacoronavirus Sax-2011, Nyctalus velutinus alfacoronavirus SC-2013, porcine epidemic diarrhea virus, Scotophilus bat coronavirus 512, Rhinolophus bat coronavirus HKU2, rczonn / zznz / E / YiAi 141 human coronavirus NL63, bat coronavirus strain related to NL63 BtKYNL63~9b, Alfacoronavirus 1. As used herein, the term Betacoronavirus refers to the corresponding family of the Baltimore classification, which includes the subgenera Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, and Sarbecovirus. Non-exhaustively, this includes the following species: Betacoronavirus 1, Chinese rat coronavirus HKU24, human coronavirus HKU1, murine coronavirus, Hp-betacoronavirus Zhej iang 2013 from bat, Hedgehog coronavirus 1, respiratory syndrome-related coronavirus Middle East, Pipistrellus bat coronavirus HKU5, Tylonycteris bat coronavirus HKU4, Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus, Pipistrellus bat coronavirus HKU5, Tylonycteris mucilage coronavirus HKU4, bat coronavirus GCCDC1 of Rousettus, Rousettus bat coronavirus HKU9, coronavirus related to severe acute respiratory syndrome. As used herein, the term corona virus related to severe acute respiratory syndrome or SARS virus includes, but is not limited to, SARS-CoV, SARSr-CoV WIV1, SARSr-CoV HKU3, SARSr-CoV RP3 and SARS-CoV-2; including strains responsible for COVIDrczonn / zznz / E / YiAi 142 and its mutants. As used herein, the term Deltacoronavirus refers to the corresponding family of the Baltimore classification, which includes the subgenera Andecovirus, Buldecovirus, Herdecovirus, and Moordecovirus. Non-exhaustively, this includes the following species: Wigeon coronavirus HKU20, Bulbul coronavirus HKU11, Muñía coronavirus HKU15, Muñía coronavirus HKU13, White-eye coronavirus HKU16, Night heron coronavirus HKU19, Moorhen coronavirus HKU21. As used herein, the term Gammacoronavirus refers to the corresponding family of the Baltimore classification, which includes the subgenera Cegacovirus and Igacovirus. Non-exhaustively, this includes the following species: beluga whale coronavirus SW1 and avian coronavirus. According to particular embodiments, the co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, the pharmaceutically acceptable salt of 8-chloro-N-( 4-(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use in a method of treating or prevent a Coronaviridae infection, is to reduce inflammation associated with rczonn / zznz / E / YiAi 143 Coronaviridae infection. According to particular embodiments, the co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, the pharmaceutically acceptable salt of 8-chloro-N-( 4-(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use in a method of treating or prevent a Coronaviridae infection, is to reduce the viral load of Coronaviridae. According to particular embodiments, the co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, the pharmaceutically acceptable salt of 8-chloro-N-( 4-(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, for use in a method of treating or prevent a Coronaviridae infection, is in combination with: - a dynamin inhibitor, such as Dynasore; I - an antibiotic, such as one selected from the group consisting of beta-lactams, fluoroquinolones and macrolides, such as azithromycin; rczonn / zznz / E / YiAi - remdesivir; 144 - ribavirin; - ritonavir; - lopanivir; - chloroquine or hydroxychloroquine; - interferon beta; an anti-inflammatory compound, such as one selected from the group consisting of: anti-TNF, Jak inhibitors, anti-IL6 antibodies, IL6 receptor antagonists; and / or - a calcium inhibitor such as diltiazem. According to some particular modalities, the Corona viridae is selected from Letovirinae and Orthocoronavirinae. According to some particular embodiments, the Coronaviridae is an Alphacoronavirus or a Betacoronavirus or a Deltacoronavirus or a Gammacoronavirus. According to some particular embodiments, the Coronaviridae is an Embecovirus or a Hibecovirus or a Merbecobivirus or a Nobecovirus or a Sarbecovirus. According to some particular modalities, Coronaviridae is a Sarbecovirus selected from coronaviruses related to Severe Acute Respiratory Syndrome. According to some particular modalities, coronaviruses related to Acute Respiratory Syndrome rczonn / zznz / E / YiAi 145 Severe (SARS) are selected from the group formed by: SARS-CoV, SARSr-CoV WIV1, SARSr-CoV HKU3, SARSr-CoV RP3, SARS-CoV-2. According to some preferred embodiments, Severe Acute Respiratory Syndrome (SARS)-related coronaviruses are selected from SARS-CoV and SARS-CoV-2; including the strains responsible for COVID-19 and its mutants. According to some embodiments, the co-crystal of 8-chloroN-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, the pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy) )phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention, are used in a method to treat or prevent a Coronaviridae infection, in which the level of free base equivalent of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine, in a sample of blood, plasma, tissue, saliva, pharynx, tracheal , bronchoalveolar and / or patient serum, is measured during use. Cancers A co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin- 2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition such as 146 is defined in the present invention, may be useful in the treatment or prevention of various types of cancer. As used herein, the term cancer, unless otherwise indicated, can relate to any disorder associated with abnormal cell growth, including malignant tumors and benign tumors, metastatic tumors and non-metastatic tumors, solid tumors and non-solid tumors, such as blood-related cancers which may include leukemia, lymphoma and myeloma; It may also be linked to cancers of the Central Nervous System (CNS) and non-CNS cancers. Unless otherwise stated, the term cancer also encompasses juvenile and non-juvenile cancers, recurrent and non-recurrent cancers, and cancer relapses. Cancers include the following: blood-related cancer, pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, hepatocellular cancer, thyroid cancer , gallbladder cancer, lung cancer (eg, non-small cell lung cancer, small cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, cancer head and neck, melanoma, neuroendocrine cancer, CNS cancer, tumors rczonn / zznz / E / YiAi 147 brain (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, periphoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms , hemangiopericytomas, Kaposi sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, squamous cell carcinomas of the esophagus, oral carcinomas, cancers of the adrenal cortex, or ACTH-producing tumors. According to one embodiment, the following cancers can be mentioned: head and neck cancer, stomach cancer, breast cancer, basal and squamous cell skin cancer, liver cancer, kidney cancer, brain cancer, lung cancer. , pancreatic cancer, eye cancer, gastrointestinal cancer, colorectal cancer, esophageal cancer, colorectal cancer, bladder cancer, gallbladder cancer, thyroid cancer, melanoma, uterine / cervical cancer, ovarian cancer, bone cancer and Kidney cancer. According to another embodiment, the cancer can be selected from head and neck cancer, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the neck, acute lymphocytic leukemia (ALL) in adults or children, acute myeloid leukemia (AML) in adults or children, leukemia rczonn / zznz / E / YiAi 148 acute lymphoblastic, adrenal cancer, anal cancer, astrocytic glioma, astrocytoma (grade I, II, III or IV), B-cell or NK / T lymphomas, basal and squamous skin cell cancer, bile duct cancer, bladder, bone cancer, brain cancer, brain and spinal cord tumors in adults, brain and spinal cord tumors in children, anaplastic astrocytomas, breast cancer, gastrointestinal cancer, breast cancer in women, breast cancer in young women, breast cancer in men, recurrent breast cancer, hereditary breast cancer, HER2 positive breast cancer, breast cancer associated with lymph node metastasis, ER-alpha positive breast cancer, cancer in adolescents, cancer in children, cancer in young adults, cancer of unknown primary, Castleman disease, cervical cancer, cervical intraepithelial neoplasia, cholangiocarcinoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML), colorectal cancer, colorectal adenoma, cutaneous squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, epithelial ovarian cancer associated with metastasis, esophageal cancer, cell carcinoma esophageal squamous cell carcinoma, Ewing sarcoma, Ewing family tumors, lymphoblastic leukemia (ALL), eye cancer, such as melanoma and lymphoma rczonn / zznz / E / YiAi 149 ocular, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor (GIST), gestational trophoblastic disease, glioblastoma, glioblastoma multiforme (GBM), hairy cell leukemia, glioma, glioma high grade, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, invasive ductal breast carcinoma, Hodgkin lymphoma, Kaposi sarcoma, kidney cancer, laryngeal cancer and hypopharyngeal cancer, leiomyosarcoma, leukemia, leukemia in children, liver cancer, lung cancer , carcinoid tumor of the lung, Lymphoma, skin lymphoma, malignant mesothelioma, mantle cell lymphoma, medulloblastoma, melanoma skin cancer, malignant melanoma, meningioma, Merkel cell skin cancer, multiple myeloma, multiple myeloma with osteonecrosis of the jaw, myelodysplastic syndrome, cancer of the nasal cavity and paranasal sinuses, cancer of the nasopharynx, recurrent or metastatic carcinoma of the nasopharynx, neuroblastoma, neuroglioma, non-Hodgkin lymphoma, non-Hodgkin lymphoma in children, non-small cell lung cancer, cancer gefitinib-resistant non-small cell lung cancer, oral cancer, oral cavity and oropharyngeal cancer, osteosarcoma, metastatic pulmonary osteosarcoma, ovarian cancer, pancreatic cancer, thyroid carcinoma, papillary thyroid carcinoma, pediatric spinal ependymoma, penis, pituitary tumors, pituitary adenoma, rczonn / zznz / E / YiAi 150 proneural tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma tongue cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, kidney cancer, retinoblastoma, Waldenstrom's macroglobulinemia and Wilms tumor. According to another embodiment, the cancer may be selected from head and neck squamous cell carcinoma, neck squamous cell carcinoma, acute lymphocytic leukemia (ALL) in adults or children, acute myeloid leukemia (AML) in adults or children, acute lymphoblastic leukemia, adrenal cancer, anal cancer, astrocytic glioma, astrocytoma (grade I, II, III or IV), B-cell or NK / T lymphomas, basal and squamous skin cell cancer, bile duct cancer, bones, brain cancer, brain cancer and spinal cord tumors in adults, brain and spinal cord tumors in children, anaplastic astrocytomas, gastrointestinal cancer, breast cancer in women, breast cancer in young women, breast cancer in men, recurrent breast cancer, hereditary breast cancer, HER2-positive breast cancer, breast cancer associated with lymph node metastasis, breast cancer rczonn / zznz / E / YiAi 151 positive for ER-alpha, cancer in adolescents, cancer in children, cancer in young adults, cancer of unknown primary origin, Castleman disease, cervical intraepithelial neoplasia, cholangiocarcinoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), colorectal adenoma, cutaneous squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, epithelial ovarian cancer associated with metastasis, esophageal squamous cell carcinoma, Ewing sarcoma, Ewing family of tumors, lymphoblastic leukemia (ALL), eye cancer, such as melanoma and ocular lymphoma, gastric cancer, gastrointestinal carcinoid tumors, Gastrointestinal stromal tumor (GIST), gestational trophoblastic disease, glioblastoma, glioblastoma multiforme (GBM), hairy cell leukemia, glioma , high-grade glioma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, invasive ductal breast carcinoma, Hodgkin lymphoma, Kaposi sarcoma, laryngeal and hypopharyngeal cancer, leiomyosarcoma, leukemia, leukemia in children, lung carcinoid tumor, lymphoma, lymphoma of the skin , malignant mesothelioma, mantle cell lymphoma, medulloblastoma, malignant melanoma, meningioma, Merkel cell skin cancer, multiple myeloma, multiple myeloma with osteonecrosis of the jaw, myelodysplastic syndrome, cancer of the nasal cavity and paranasal sinuses, cancer of the nasopharynx , nasopharyngeal carcinoma 152 recurrent or metastatic, neuroblastoma, neuroglioma, non-Hodgkin lymphoma, non-Hodgkin lymphoma in children, non-small cell lung cancer resistant to gefitinib, oral cancer, oral cancer of the oral cavity and oropharynx, osteosarcoma, metastatic pulmonary osteosarcoma, thyroid carcinoma , papillary thyroid carcinoma, pediatric spinal ependymoma, penile cancer, pituitary tumors, pituitary adenoma, proneural tumors, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, small cell lung cancer, small intestine cancer, sarcoma soft tissue, squamous cell carcinoma of the tongue, testicular cancer, thymus cancer, uterine sarcoma, vaginal cancer, vulvar cancer, renal cancer, retinoblastoma, Waldenstrom's macroglobulinemia, and Wilms tumor. According to a further embodiment, the cancer may be selected from head and neck cancer, head and neck squamous cell carcinoma, neck squamous cell carcinoma, malignant melanoma, stomach cancer, breast cancer, female breast cancer. , breast cancer in young women, basal cancer and squamous cell skin cancer, liver cancer, brain cancer, anaplastic astrocytomas, lung cancer, non-small cell lung cancer, refractory non-small cell lung cancer a gefitinib, oral cancer, eye cancer, gastric cancer, gastrointestinal cancer, astrocytic glioma, astrocytoma rczonn / zznz / E / YiAi 153 (grade I, II, III or IV), colorectal cancer, colorectal adenoma, cutaneous squamous cell carcinoma, bladder cancer, bone cancer, recurrent breast cancer, hereditary breast cancer, HER2 positive breast cancer, breast cancer breast associated with lymph node metastasis, ER-alpha positive breast cancer, renal cancer, cervical intraepithelial neoplasia, cholangiocarcinoma, leiomyosarcoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), leukemia acute myeloid (AML) in adults or children, acute lymphoblastic leukemia, B-cell or NK / T lymphomas, cervical cancer, glioblastoma, glioblastoma multiforme (GBM), hairy cell leukemia, glioma, high-grade glioma, hepatocellular carcinoma , intrahepatic cholangiocarcinoma, invasive ductal breast carcinoma, kidney cancer, endometrial cancer, ovarian cancer, epithelial ovarian cancer, epithelial ovarian cancer associated with metastasis, esophageal cancer, esophageal squamous cell carcinoma, Ewing's sarcoma, lymphoblastic leukemia (ALL), mantle cell lymphoma, medulloblastoma, lymphoma, myelodysplastic syndrome, meningioma, multiple myeloma (MM), multiple myeloma with osteonecrosis of the jaw, nasopharyngeal cancer, recurrent or metastatic nasopharyngeal carcinoma, neuroblastoma, neuroglioma, papillary thyroid carcinoma, pediatric spinal ependymoma, osteosarcoma, osteosarcoma 154 metastatic lung, pancreatic cancer, thyroid carcinoma, sarcoma, pituitary tumors, pituitary adenoma, proneural tumors, squamous cell carcinoma of the tongue, mesothelioma, retinoblastoma and prostate cancer. According to a further embodiment, the cancer may be selected from head and neck cancer, head and neck squamous cell carcinoma, neck squamous cell carcinoma, malignant melanoma, astrocytic glioma, glioma, stomach cancer, breast cancer, cholangiocarcinoma, recurrent or metastatic nasopharyngeal carcinoma, basal and squamous cell skin cancer, liver cancer, brain cancer, anaplastic astrocytomas, lung cancer, non-small cell lung cancer, refractory non-small cell lung cancer gefitinib, oral cancer, glioblastoma, osteosarcoma, pulmonary metastatic osteosarcoma, pancreatic cancer, eye cancer, gastrointestinal cancer, colorectal cancer, colorectal adenoma, cutaneous squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, esophageal cancer, sarcoma Ewing's disease, gastric cancer, hepatocellular carcinoma, HER2 positive breast cancer, bladder cancer, bone cancer, prostate cancer, retinoblastoma and kidney cancer. According to a further embodiment, the cancer can be selected from anaplastic astrocytomas, astrocytic gliomas, bladder cancer, breast cancer, rczonn / zznz / E / YiAi 155 cholangiocarcinoma, colorectal cancer, colorectal adenoma, cutaneous squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, esophageal cancer, Ewing sarcoma, gastric cancer, gefitinib-resistant non-small cell lung cancer, glioblastoma, glioma, hepatocellular carcinoma, HER2 positive breast cancer, head and neck squamous cell carcinoma, malignant melanoma, nasopharyngeal carcinoma (recurrence or metastasis), neck squamous cell carcinoma, non-small cell lung cancer, oral cancer, osteosarcoma, osteosarcoma (lung metastasis), prostate cancer and retinoblastoma. According to a further embodiment, the cancer can be selected from anal cancer, bile duct cancer, gastrointestinal cancer, cholangiocarcinoma, colorectal cancer, colorectal adenoma, esophageal cancer, squamous cell carcinoma of the esophagus, gastric cancer, gastrointestinal carcinoid tumors, tumor of the gastrointestinal stroma (GIST), hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liver cancer, lung cancer, lung carcinoid tumor, non-small cell lung cancer, gefitinib-resistant non-small cell lung cancer, metastatic pulmonary osteosarcoma, lung cancer stomach, pancreatic cancer, small cell lung cancer, and small intestine cancer. According to one modality, the patient does not present 156 clinically detectable metastasis, in particular such patient has a precancerous condition, an early stage cancer or a non-metastatic cancer, or such patient presents clinically detectable metastases and such 8-chloro-N-(4(trifluoromethoxy)phenyl co-crystal )quinolin-2-amine as defined in the present invention, or such pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof as defined in the present invention does not directly target metastatic invasion. In view of the above, the invention relates to a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use in the treatment and / or prevention of cancer, such as the cancers listed here above, and dysplasia. Therefore, the invention also relates to the use of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro- N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine which rczonn / zznz / E / YiAi 157 includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for treating and / or preventing cancer, such as the cancers and dysplasia mentioned above. The invention also relates to the use of a cocrystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4( trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention for the preparation of a composition, such as a medicament, for treating and / or preventing cancer, such such as the cancers and dysplasia mentioned above. The invention also relates to a method for preventing, inhibiting or treating cancer or dysplasia, which comprises at least one step consisting of administering to a patient suffering from them an effective amount of a co-crystal of 8-chloro-N -(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention. In some embodiments, the invention relates to rczonn / zznz / E / YiAi 158 with a method of the present invention or a co-crystal of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N- (4-(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use as defined above, to treat and / or prevent cancer or dysplasia, in which the presence and / or expression level of miR-124 is measured in a blood and / or tissue sample from the patient before and / or during use. In some embodiments, the invention relates to a method of the present invention or a co-crystal of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for its use as defined above, to treat and / or prevent cancer or dysplasia, in which the presence and / or expression level of miR-124 is measured in a blood and / or tissue sample to guide dosage or monitor response to treatment. In some embodiments, the invention relates 159 with a method of the present invention or a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N- (4-(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use as defined above, to treat and / or prevent cancer or dysplasia, in which the level of free base equivalent of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine, in blood, plasma, tissue, saliva , and / or patient serum sample, is measured during use. In some embodiments, the invention relates to a method of the present invention or a co-crystal of 8chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for its use as defined above, to treat and / or prevent cancer or dysplasia, used in combination with another antitumor agent. In some embodiments, the invention relates to a method of the present invention or an 8 rczonn / zznz / E / YiAi co-crystal 160 chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine that includes a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use as defined above, to treat and / or prevent cancer or dysplasia, which It is used in combination with other therapy selected from chemotherapy, immunotherapy, radiation therapy, surgery, ultrasound, monoclonal antibodies, and cancer vaccines. Among other anti-cancer medications, the following can be mentioned: - Androgen receptor inhibitors, such as enzalutamide (Xtandi®, Astellas / Medivation), abiraterone (Zytiga®, Centocor / Ortho), gonadotropin-releasing hormone (GnRH) receptor antagonist such as degaralix, Firmagon®, Ferring Pharmaceuticals) Antiapoptotics, such as venetoclax (Venclexta®, AbbVie / Genentech), blinatumomab (Blincyto®, Amgen), navitoclax (ABT-263, Abbott); - Antiproliferative and antimitotic agents, such as vinca alkaloids (including vinblastine, vincristine); rczonn / zznz / E / YiAi - Antibiotics such as dactinomycin daunorubicin 161 doxorubicin, idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; - L-asparaginase; - Antiplatelet agents; Antiproliferative / antimitotic alkylating agents such as nitrogen mustards, cyclophosphamide and analogues (including melphalan, chlorambucil, hexamethylmelamine and thiotepa), alkyl nitrosoureas (including carmustine) and analogues, streptozocin and triazenes (including dacarbazine); - Antiproliferative / antimitotic antimetabolites such as folic acid analogues (including methotrexate), aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds that induce cellular differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platinum compounds; compounds targeting / reducing the activity of a protein or lipid kinase and other antiangiogenic compounds; compounds that target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; antiandrogens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; rczonn / zznz / E / YiAi 162 bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of oncogenic Ras isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematological malignancies; compounds that target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (17allylaminogeldanamycin, NSC330507), 17-DMAG (17dimethylaminoethylamino-17-desmethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010 from Conforma Therapeutics; temozolomide (Temodal®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine / chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array BioPharma, AZdg244 from AstraZeneca, PD181461 from Pfizer and leucovorin; - Anti-immigration agents; - Angiogenesis inhibitors, such as TNP-470; Aromatase inhibitors, such as letrozole and anastrozole, exemestane; - Angiotensin - Antisense oligonucleotides, such as antisense nucleic acids directed towards miR-124; - Anticoagulants, such as heparin, synthetic heparin salts and other thrombin inhibitors; - Arginine inhibitors, such as AEB1102 (arginase rczonn / zznz / E / YiAi pegylated recombinant 163, Aeglea Biotherapeutics) and CB-1158 (Calithera Biosciences); - Bone resorption inhibitors, such as Denosumab (Xgeva®, Amgen), bisphosphonates such as zoledronic acid (Zometa®, Novartis); CC chemokine receptor 4 (CCR4) inhibitors, such as mogamulizumab (Boteligeo®, Kyowa Hakko Kirin, Japan); - CDK inhibitors, such as CDK4 / CDK6 inhibitors, such as palbociclib (Ibrance®, Pfizer); ribociclib (Kisqali®, Novartis); abemaciclib (Ly2835219, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics); - Cell cycle inhibitors and differentiation inducers, such as tretinoin; - Corticosteroids, such as cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone and prednisolone; DNA-damaging agents such as actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide (CYTOXAN®), dactinomycin, daunorubicin, doxorubicin, epirubicin, ifosfamide, melphalan, merchlorethamine, mitomycin, mitoxantrone, nitrosourea, procarbazine, taxol, taxotere, teniposide, etoposide and triethylenethiophosphoramide; Fibrinolytic agents, such as tissue plasminogen activator, streptokinase, urokinase, aspirin, rczonn / zznz / E / YiAi 164 dipyridamole, ticlopidine and clopidogrel; - Folate antagonists; - FLT3 receptor inhibitors, such as enzalutamide, abiraterone, apalutamide, erlotinib, crizotinib, niraparib, olaparib, osimertinib, regorafenib, sunitinib, lestaurtinib, midostaurin, gilteritinib, semaxinib, linifanib, fostamatinib, pexidartinib, sorafenib, cabozantinib, ponatinib, ilosertib, pacritinib , famitinib, pexidartinib, qui zartinib; Glutaminase inhibitors, such as CD-839 (Calithera Biosciences); - Growth factor signal transduction kinase inhibitors; - Growth factor inhibitors, such as vascular endothelial growth factor inhibitors and fibroblast growth factor inhibitors, such as olaratumab (Lartruvo®; Eli Lilly), cetuximab (Erbitux®, Eli Lilly); necitumumab (Portrazza®, Eli Lilly), panitumumab (Vectibix®, Amgen); and osimertinib (targeting activated EGFR, Tagrisso®, AstraZeneca); - Hedgehog pathway inhibitors, such as sonidegib (Odomzo®, Sun Pharmaceuticals); and vismodegib (Erivedge®, Genentech); - Histone deacetylase (HDAC) inhibitors, such as vorinostat (Zolinza®, Merck); romidepsin (Istodax®, Celgene); rczonn / zznz / E / YiAi 165 panobinostat (Farydak®, Novartis); belinostat (Beleodaq®, Spectrum Pharmaceuticals); entinostat (SNDX-275, Syndax Pharmaceuticals) (NCT00866333); and chidamide (Epidaza®, HBI8000, Chipscreen Biosciences, China); - Hormones and their analogues, such as estrogen, tamoxifen, goserelin, bicalutamide and nilutamide); - isocitrate dehydrogenase (IDH) inhibitors, such as AG120 (Celgene; NCT02677922); AG221 (Celgene, NCT02677922; NCT02577406); BAY1436032 (Bayer, NCT02746081) ; IDH305 (Novartis, NCT02987010) - Isoflavones such as genistein; immunosuppressants, such as tacrolimus, sirolimus, azathioprine, and mycophenolate; - Inhibitors of p53 suppressor proteins, such as ALRN-6924 (Aileron); Transforming growth factor-beta (TGF-beta or TGFB) inhibitors, such as NIS793 (Novartis), fresolimumab (GC1008; Sanofi-Genzyme), M7824 (Merck KgaA formerly MSB0011459X); - iNKT cell agonists such as ABX196 5Abivax) - mTOR inhibitors, such as everolimus (Afinitor®, Novartis); temsirolimus (Torisel®, Pfizer); and sirolimus (Rapamune®, Pfizer); - Microtubule inhibitor drugs, such as taxanes (including paclitaxel, docetaxel), vinblastine, nocodazole, rczonn / zznz / E / YiAi 166 epothilones, vinorelbine) (NAVELBINE®) and epipodophyllotoxins (etoposide, teniposide); - nitric oxide donors; Nucleoside inhibitors, such as trabectedin (guanidine alkylating agent, Yondelis®, Janssen Oncology), mechlorethamine (alkylating agent, Valchlor®, Aktelion Pharmaceuticals); vincristine (Oncovin®, Eli Lilly; Vincasar®, Teva Pharmaceuticals; Marqibo®, Talón Therapeutics); temozolomide (prodrug of the alkylating agent 5—(3—methyltriazen-l-yl)-imidazole-4-carboxamide (MTIC) Temodar®, Merck); cytarabine injection (ara-C, antimetabolic cytidine analogue, Pfizer); lomustine (alkylating agent, CeeNU®, Bristol-Myers Squibb; Gleostine®, NextSource Biotechnology); azacitidine (pyrimidine nucleoside analogue of cytidine, Vidaza®, Celgene); omacetaxine mepesuccinate (cephalotaxine ester) (protein synthesis inhibitor, Synribo®; Teva Pharmaceuticals); Erwinia chrysanthemi asparaginase (asparagine depletion enzyme, Elspar®, Lundbeck; Erwinaze®, EUSA Pharma); eribulin mesylate (microtubule inhibitor, tubulin-based antimitotic, Halaven®, Eisai); cabazitaxel (microtubule inhibitor, tubulin-based antimitotic, Jevtana®, Sanofi-Aventis); capacetrin (thymidylate synthase inhibitor, Xeloda®, Genentech); bendamustine (bifunctional mechlorethamine derivative, believed to form DNA cross-links rczonn / zznz / E / YiAi 167 interstrand, Treanda®, Cephalon / Teva); ixabepilone (semi-synthetic analogue of epothilone B, microtubule inhibitor, tubulin-based antimitotic, Ixempra®, Bristol-Myers Squibb); nelarabine (deoxyguanosine analog prodrug, nucleoside metabolic inhibitor, Arranon®, Novartis); chlorafabine (prodrug of ribonucleotide reductase inhibitor, competitive deoxycytidine inhibitor, Clolar®, Sanofi-Aventis); and trifluridine and tipiracil (thymidine-based nucleoside analogue and thymidine phosphorylase inhibitor, Lonsurf®, Taiho Oncology); - PI3K inhibitors, such as idelalisib (Zydelig®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech / Roche); pictilisib (GDC-0941, Genentech / Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); and TGR1202 (previously RP5230, TG Therapeutics); Platinum coordination complexes (such as cisplatin, oxyloplatin, carboplatin, nedaplatin, picoplatin, procarbazine, mitotane, satraplatin, and aminoglutethimide; - Poly ADB ribose polymerase (PARP) inhibitor, such as those selected from: olaparib (Lynparza®, AstraZeneca); rucaparib (Rubraca®, Clovis Oncology); niraparib (Zejula®, Tesaro); talazoparib (MDV3800 / BMN 673 / LT00673, Medivation / Pfizer / Biomarin); veliparib (ABT-888, AbbVie); and rczonn / zznz / E / YiAi 168 BGB-290 (BeiGene, Inc.); Proteasome inhibitors, such as everolimus (Afinitor®, Novartis); temsirolimus (Torisel®, Pfizer); and sirolimus (Rapamune®, Pfizer), bortezomib (Velcade®, Takeda); carfilzomib (Kyprolis®, Amgen); and ixazomib (Ninlaro®, Takeda); - Pyrimidine and purine analogues, such as floxuridine, capecitabine and cytarabine; receptor blockers, antisecretory agents, such as abreldine; Selective estrogen receptor modulator (SERM), such as raloxifene (Evista®, Eli Lilly); - Therapeutic antibodies, such as those selected from: anti-TNF antibodies, anti-VEGF antibodies, anti-EGFR antibodies, anti-PD-1 antibodies, anti-HER2 antibodies, anti-CD20 antibodies, anti-IL17 antibodies and anti-CTLA4 antibodies , anti-PDLl, anti-CD25, antia4integrin, anti-IL6R, anti-C5, anti-ILl, anti-TPO, antiIL12 / 23, anti-EPCAM / CD3, anti-CD30, anti-CD80 / 86, antianthrax, anti -CCR4, anti-CD6, anti-CD19, anti-4p7, anti-IL6, anti-VEGFR-2, anti-SLAMF7, anti-GD2, anti-IL17A, anti-PCSK9, anti-IL5, anti-CD22, anti-IL4, anti-PDGFRa, anti-IL17RA and anti-TcdB, and such as those selected from: Abagovomab, Abatacept, Abciximab, Abituzumab, Abrilumab, Actoxumab, Adalimumab, Adecatumab, Aducanumab, Aflibercept, Afutuzymab, Alacizumab, Alefacept, Alemtuzumab , Alirocumab, Altumomab, rczonn / zznz / E / YiAi 169 Amatixumab, Anatumomab, Anetumab, Anifromumab, Anrukinzumab, Apolizumab, Arcitumomab, Ascrinvacumab, Aselizumab, Atezolizumab, Atinumab, Altizumab, Atorolimumab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Begelomab, Belatacept, Belimumab, Benralizumab, Bertilimumab, Besilesomab, Bevacizumab , Bezlotoxumab, Biciromab, Bimagrumab, Bimekizumab, Bivatuzumab, Blinatumomab, Blosozumab, Bococizumab, Brentuximab, Briakimumab, Brodalumab, Brolucizumab, Bronticizumab, Canakinumab, Cantuzumab, Caplacizumab, Capromab, Carlumab, Catumaxomab, Cedelizumab, Certolizumab, Cetixumab, Citatuzumab, Cixutumumab, Clazaki zumab, Clenoliximab, Clivatuzumab, Codrituzumab, Coltuximab, Conatumumab, Concizumab, Crenezumab, Dacetuzumab, Daclizumab, Dalotuzumab, Dapirolizumab, Daratumumab, Dectrekumab, Demcizumab, Denintuzumab, Denosumab, Derlotixumab, Detumomab, Dinutuximab, Diridavumab, Dorlinomab, Drozitumab, Dupilumab, Durvalumab, Dusigit umab, Ecromeximab, Eculizumab, Edobacomab, Edrecolomab, Efalizumab, Efungumab, Eldelumab, Elgemtumab, Elotuzumab, Elsilimomab, Emactuzumab, Emibetuzumab, Enavatuzumab, Enfortumab, Enlimomab, Enoblituzumab, Enokizumab, Enoticumab, Ensituximab, Epitumomab, Epratuzomab, Erlizumab, Ertumaxomab, Etanercept, Etaracizumab, Etrolizumab, Evinacumab, Evolocumab, Exbivirumab, Fanolesomab, Faralimomab, Farletuzomab, Fasimumab, rczonn / zznz / E / YiAi 170 Felvizumab, Fezkimumab, Ficlatuzumab, Figitumumab, Firivumab, Flanvotumab, Fletikumab, Fontolizumab, Foralumab, Foravirumab, Fresolimumab, Fulramumab, Futuximab, Galiximab, Ganitumab, Gantenerumab, Gavilimomab, Gemtuzumab, Gevokizumab, Girentumabumab, Glembatumumab, Golimumab, Gomiliximab, Guselkumab, Ibal izumab, Ibritumomab, Icrucumab, Idarucizumab, Igovomab, Imalumab, Imciromab, Imgatuzumab, Inclacumab, Indatuximab, Indusatumab, Infliximab, Intetumumab, Inolimomab, Inotuzumab, Ipilimumab, Iratumumab, Isatuximab, Itolizumab, Ixekizumab, Keliximab, Labetuzumab, Lambrolizumab, Lampalizumab, Le brikizumab, lemalesomab, Lenzilumab, Lerdelimumab, Lexatumumab, Libivirumab, Lifastuzumab, Ligelizumab, Lilotomab, Lintuzumab, Lirilumab, Lodelcizumab, Lokivetmab, Lorvotuzumab, Lucatumumab, Lulizumab, Lumiliximab, Lumretuzumab, Mapatumumab, Margetuximab, Maslimomab, Mavrilimumab, Matuzumab, Mepolizumab, Metelimumab , Milatuzumab, Minetumomab, Mirvetuximab, Mitumomab, Mogamulizumab, Morolimumab, Motavizumab, Moxetumomab, Muromonab-CD3, Nacolomab, Namilumab, Naptumomab, Narnatumab, Natalizumab, Nebacumab, Necitumumab, Nemolizumab, Nerelimomab, Nesvacumab, Nimotuzumab, Nivolumab, Nofetumomab, Obiltoxaximab, Obinutuz umab, Ocaratuzumab, Ocrelizumab, Odulimomab, Ofatumumab, Olaratumab, Olokizumab, Omalizumab, Onartuzumab, Ontuxizumab, Opicinumab, Oportuzumab, Oregovomab, Orticumab, rczonn / zznz / E / YiAi 171 Otelixizumab, Oltertuzumab, Oxelumab, Ozanezumab, Ozoralizumab, Pagibaximab, Palivizumab, Panitumumab, Pankomab, Panobacumab, Parsatuzumab, Pascolizumab, Pasotuxizumab, Pateclizumab, Patritumab, Pembrolizumab, Pemtumomab, Perakizumab, Pertuzumab, Pexelizumab, Pidilizumab, Pinatuzumab, Pintumomab , Polatuzumab, Ponezumab, Priliximab, Pritumumab, Quilizumab, Racotumomab, Radretumab, Rafivirumab, Ralpancizumab, Ramucirumab, Ranibizumab, Raxibacumab, Refanezumab, Regavirumab, Reslizumab, Rilonacept, Rilotumumab, Rinucumab, Rituximab, Robatumumab, Roledumab, Romosozumab, Rontalizumab, Rovelizumab, Ruplizumab, Sacituzumab , Samalizumab, Sarilumab, Satumomab, Secukimumab, Seribantumab, Setoxaximab, Sevirumab, Sibrotuzumab, Sifalimumab, Siltuximab, Siplizumab, Sirukumab, Sofituzumab, Solanezumab, Solitomab, Sonepcizumab, Sontuzumab, Stamulumab, Sulesomab, Suvizumab, Tabalumab, Tacatuzumab, Tadocizumab, Talizumab, Tanezumab, Taplitumomab , Tarextumab, Tefibazumab, Telimomab aritox, Tenatumomab, Teneliximab, Teplizumab, Tesidolumab, TGN 1412, Ticlimumab, Tildrakizumab, Tigatuzumab, TNX-650, Tocilizumab, Toralizumab, Tosatoxumab, Tositumomab, Tovetumab, Tralokimumab, Trastuzumab, TRBS07, Tregalizumab, Tremelimumab, Trevogrumag, Tucotuzumab, Tuvirumab, Ublituximab, Ulocuplumab, Urelumab, Urtoxazumab, Ustekimumab, Vandortuzumab, Vantictumab, Vanucizumab, Vapaliximab, rczonn / zznz / E / YiAi 172 Varlimumab, Vatelizumab, Vedolizumab, Veltuzumab, Vepalimomab, Vesencumab, Visilizumab, Volocixumab, Vorsetuzumab, Votumumab, Zalutumimab, Zanolimumab, Zatuximab, Ziralimumab, Ziv-Aflibercept, and Zolimomab; Topoisomerase inhibitors, such as doxorubicin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan, mitoxantrone, topotecan, and irinotecan; - Toxins, such as cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, diphtheria toxin and caspase activators; Kinase or VEGF inhibitors, such as regorafenib (Stivarga®, Bayer); vandetanib (Caprelsa®, AstraZeneca); axitinib (Inlyta®, Pfizer); and lenvatinib (Lenvima®, Eisai); Raf inhibitors, such as sorafenib (Nexavar®, Bayer AG, and Onyx); dabrafenib (Tafinlar®, Novartis); and vemurafenib (Zelboraf®, Genentech / Roche); MEK inhibitors, such as cobimetanib (Cotellic®, Exelexis / Genentech / Roche); trametinib (Mekinist®, Novartis); Bcr-Abl tyrosine kinase inhibitors, such as imatinib (Gleevec®, Novartis); nilotinib (Tasigna®, Novartis); dasatinib (Sprycel®, BristolMyersSquibb); bosutinib (Bosulif®, Pfizer); and ponatinib (Inclusig®, Arlad Pharmaceuticals); Her2 and EGFR inhibitors, such as gefitinib (Iressa®, AstraZeneca); erlotinib (Tarceeva®, rczonn / zznz / E / YiAi 173 Genentech / Roche / Astellas); lapatinib (Tykerb®, Novartis); afatinib (Gilotrif®, Boehringer Ingelheim); osimertinib (targeting activated EGFR, Tagrisso®, AstraZeneca); and brigatinib (Alunbrig®, Ariad Pharmaceuticals); c-Met and VEGFR2 inhibitors, such as cabozanitib (Cometriq®, exélexis); and multikinase inhibitors, such as sunitinib (Sutent®, Pfizer); pazopanib (Votrient®, Novartis); ALK inhibitors, such as crizotinib (Xalkori®, Pfizer); ceritinib (Zykadia®, Novartis); and alectinib (Alecenza®, Genentech / Roche); Bruton's tyrosine kinase inhibitors, such as ibrutinib (Imbruvica®, Pharmacyclics / Janssen); and Flt3 receptor inhibitors, such as midostaurin (Rydapt®, Novartis), tivozanib (Aveo Pharmaecuticals); vatalanib (Bayer / Novartis); lucitanib (Clovis Oncology); dovitinib (TKI258, Novartis); Chiauanib (Chipscreen Biosciences); CEP-11981 (Cephalon); linifanib (Abbott Laboratories); neratinib (HKI-272, Puma Biotechnology); radotinib (Supect®, IY5511, Il-Yang Pharmaceuticals, South Korea); ruxolitinib (Jakafi®, Incyte Corporation); PTC299 (PTC Therapeutics); CP-547,632 (Pfizer); foretinib (Exelexis, GlaxoSmithKline); quizartinib (Daiichi Sankyo) and motesanib (Amgen / Takeda). In a non-limiting manner, the co-crystals or salts of the invention can be combined, alone or in the form of a set of pieces, with one or more of the following anticancer drugs or compounds: ABVD, AC, ACE, Abiraterone 174 (Zytiga®), Abraxane, Abstral, Actinomycin D, Actiq, adriamycin, Afatinib (Giotrif®), Afinitor, Aflibercept (Zaltrap®), Aldara, aldesleukin (IL-2, proleukin or interleukin 2), Alemtuzumab (MabCampath), Alkeran, Amsacrine (Amsidine, m-AMSA), Amsidine, Anastrozole (Arimidex®), Ara C, Aredia, Arimidex, Aromasin, Arsenic trioxide (Trisenox®, ATO), Asparaginase (Crisantaspase®, Erwinase®), Axitinib (Inlyta ®), azacitidine (Vidaza®), BEACOPP, BEAM, bendamustine (Levact®), bevacizumab (Avastin), bexarotene (Targretin®), bicalutamide (Casodex®), bleomycin, bleomycin, etoposide and platinum (BEP), bortezomib (Velcade ®), Bosulif, Bosutinib (Bosulif), Brentuximab (Adcetris®), Brufen, Buserelin (Suprefact®), Busilvex, Busulfan (Myleran, Busilvex), CAPEOX, CAPOX, CAV, CAVE, CCNU, CHOP, CMF, CMV, CVP , Cabazitaxel (Jevtana®), Cabozantinib (Cometriq®), Caelyx, Calpol, Campto, Capecitabine (Xeloda®), Caprelsa, Carbo MV, CarboTaxol, Carboplatin, Carboplatin and etoposide, Carboplatin and paclitaxel, Carmustine (BCNU, Gliadel®), Casodex, Ceritinib (Zykadia®), Cerubidine, Cetuximab (Erbitux®), ChlVPP, Chlorambucil (Leukeran®), Cisplatin, Cisplatin and Teysuno, Cisplatin and capecitabine (CX), Cisplatin, etoposide and ifosfamide (PEI), Cisplatin, fluorouracil ( 5-FU) and trastuzumab, Cladribine (Leustat®, LITAK), Clasteon, Clofarabine (Evoltra®), Co-codamol (Kapake®, Solpadol®, Tylex®), Cometriq, Cosmegen, Chrysantaspasa, Crizotinib rczonn / zznz / E / YiAi 175 (Xalkori®), cyclophosphamide, cyclophosphamide, thalidomide and dexamethasone (CTD), Ciprostat, cyproterone acetate (Cyprostat®), cytarabine (Ara C, cytosine arabinoside), cytarabine in cerebrospinal fluid, cytosine arabinoside, DHAP, DTIC , dabrafenib (Tafinlar®), dacarbazine (DTIC), Dacogen, dactinomycin (actinomycin D, Cosmegen®), Dasatinib (Sprycel), Daunorubicin, De Gramont, Decapeptyl SR, Decitabine (Dacogen®), Degarelix (Firmagon®), Denosumab ( Prolia®, , Durogesic, EC, ECF, EOF, EOX, EP, ESHAP, Effentora, Efudix, Eldisina, Eloxatina, Enzalutamide, Epirubicin (Pharmorubicin®), Epirubicin, cisplatin and capecitabine (ECX), Epirubicin, carboplatin and capecitabine (ECarboX), Eposin , Erbitux, Eribulin (Halaven®), Erlotinib (Tarceva®), Erwinase, Estracyt, Etopophos, Etoposide (Eposin®, Etopophos®, Vepesid®), Everolimus (Afinitor®), Evoltra, Exemestane (Aromasin®), FAD, FEC , chemotherapy with FEC-T, FMD, FOLFIRINOX, FOLFOX, Faslodex, Femara, Fentanyl, Firmagon, Fludara, Fludarabine (Fludara®), Fludarabine, cyclophosphamide and rituximab (FCR), fluorouracil (5FU), Flutamide, Folinic acid, fluorouracil e irinotecan (FOLFIRI), Fulvestrant (faslodex®), G-CSF, Gefitinib (Iressa), 176 GemCarbo (gemcitabine and carboplatin), GemTaxol, Gemcitabine (Gemzar), Gemcitabine and capecitabine (GemCap), Gemcitabine and cisplatin (GC), Gemcitabine and paclitaxel (GemTaxol®), Gemzar, Giotrif, Gliadel, Glivec, Gonapeptil, Depot, Goserelin ( Zoladex®), Goserelin (Zoladex®, Novgos®), Granulocyte colony-stimulating factor (G-CSF), Halaven, Herceptin, Hycamtin, Hydrea, Hydroxycarbamide (Hydrea®), Hydroxyurea, IDEX, ICE, IL-2, IPE , Ibandronic acid, Ibritumomab (Zevalin®), Ibrutinib (Imbruvica®), Ibuprofen (Brufen®, Nurofen®), Iclusig, Idarrubicin (Zavedos®), Idarubicin and dexamethasone, Idelalisib (Zydelig®), Ifosfamide (Mitoxana®), Imatinib (Glivec®), Imiquimod cream (Aldara®), Imnovid, Instanil, Interferon (Intron A), Interleukin, Intron A, Ipilimumab (Yervoy®), Iressa, Irinotecan (Campto®), Irinotecan and capecitabine (Xeliri®), Irinotecan Gramont, Modified Gramont Irinotecan, Javlor, Jevtana, Kadcyla, Kapake, Keytruda, Lanreotide (Somatuline®), Lanvis, Lapatinib (Tyverb®), Lenalidomide (Revlimid®), Letrozole (Femara®), Leukeran, Leuprorelin (Prostap® , Lutrate®), Leustat, Levact, liposomal doxorubicin, Litak, Lomustine (CCNU), Lynparza, Lysodren, MIC, MMM, MPT, MST Continus, MVAC, MVP, MabCampath, Mabthera, Maxtrex, Medroxyprogesterone acetate (Provera), Megace , Megestrol acetate (Megace®), Melphalan (Alkeran®), Mepact, Mercaptopurine (Xaluprine®), Methotrexate (Maxtrex), Methylprednisolone, Mifamurtide (Mepact®), Mitomycin C, 177 Mitotane, Mitoxana, Mitoxantrone (Mitozantrone®), Morphgesic SR, Morfina, Myleran, Myocet, Nab-paclitaxel, Nab-paclitaxel (Abraxane®), Navelbine, Nelarabine (Atriance®), Nexavar, Nilotinib (Tasigna®), Nintedanib (Vargatef®), Nipent, Nivolumab (Opdivo®), Novgos, Nurofen, Obinutuzumab (Gazyvaro®), Octreotide, Ofatumumab (Arzerra®), Olaparib (Lynparza®), Oncovin, Onkotrona, Opdivo, Oramorph, Oxaliplatin (Eloxatin), Oxaliplatin and capecitabine (Xelox®) , PAD, PC (paclitaxel and carboplatin, CarboTaxol), PCV, PE, PMitCEBO, POMB / ACE, Paclitaxel (Taxol®), Paclitaxel and carboplatin, Pamidronate, Panadol, Panitumumab (Vectibix®), Paracetamol, Pazopanib (Votrient®), Pembrolizumab (Keytruda), Pemetrexed (Alimta®), Pemetrexed and carboplatin, Pemetrexed and cisplatin, Pentostatin (Nipent®), Perjeta, Pertuzumab (Perjeta®), Pixantrone (Pixuvri®), Pixuvri, Pomalidomide (Imnovid®), Ponatinib, Potactasol , Prednisolone, Procarbazine, Proleucine, Prolia, Prostap, Provera, Purinetol, R-CHOP, R-CVP, R-DHAP, R-ESHAP, R-GCVP, RICE, Raloxifene, Raltitrexed (Tomudex®), Regorafenib (Stivarga®) , Revlimid, Rituximab, (Mabthera®), Sevredol, Sodium clodronate (Bonefos®, Clasteon®, Loron®), Solpadol, Sorafenib (Nexavar®), Spheroids (dexamethasone, prednisolone, methylprednisolone), Streptozocin (Zanosar®), Sunitinib (Sutent®), Sutent, TAC, TIP, Tafinlar, Tamoxifen, Tarceva, Targretin, Tasigna, Taxol, Taxótero, Taxótero and cyclophosphamide (TC), Temodal, rczonn / zznz / E / YiAi 178 Temozolomide, (Temodal®), Temsirolimus (Torisel®), Tepadina, Teysuno, Thalidomide, Thiotepa (Tepadina®), Thioguanine (thioguanine®, 6-TG, 6-thioguanine), Tomudex, Topotecan (Hycamtin, Potactasol), Torisel, Trabectedin (Yondelis), Trastuzumab (Herceptin®), Trastuzumab emtansine (Kadcyla®), Treosulfan, Tretinoin (Vesanoid®, ATRA), Triptorelin (Decapeptyl SR®, Gonapeptyl Depot®), Trisenox, Tylex, Tyverb, VIDE, Vandetanib (Caprelsa ®), Vargatef, VelP, Vectibix, Velbe, Velcade, Vemurafenib (Zelboraf®), Vepesid, Vesanoid, Vidaza, Vinblastina (Velbe ®), Vincristine, Vincristine, actinomycin D (dactinomycin®) and cyclophosphamide (VAC), Vincristine, actinomycin and ifosfamide (VAI), Vincristine, doxorubicin and dexamethasone (VAD), Vindesine (Eldisine®), Vinflunine (Javior®), Vinorrelbine (Navelbine®), Vismodegib (Erivedge®), Votrient, XELOX, Xalkori, Xeloda, Xgeva, Xtandi , Yervoy, Yondelis, Z-DEX, Zaltrap, Zanosar, Zavedos, Zelboraf, Zevalin, Zoladex (breast cancer), Zoladex (prostate cancer), zoledronic acid (Zometa®), Zometa, Zomorph, Zydelig, Zytiga. According to a particular embodiment, a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, or a pharmaceutically acceptable salt of 8-chloro-N-(4 -(trifluoromethoxy)phenyl)quinolin-2amine including a solvate and / or a hydrate thereof as defined herein, as described herein, may be combined with various rczonn / zznz / E / YiAi 179 chemotherapies, immunotherapy (for example, checkpoint inhibitors, monoclonal antibodies), anti-tumor vaccines, RNA vaccines, magnetic particles, intravascular microrobots, radiotherapy, surgery, ultrasound or other anti-tumor therapies. Therefore, the present invention further provides a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine as defined in the present invention, a pharmaceutically acceptable salt of 8-chloro-N-( 4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof as defined in the present invention, or a pharmaceutical composition as defined in the present invention for use as an antitumor agent intended to patients who are also treated with any of immunotherapy, anti-tumor vaccines, RNA vaccines, radiation therapy, surgery, ultrasound or other anti-tumor therapies. According to one embodiment, the present invention relates to co-crystals of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine for use as defined above, pharmaceutically acceptable salts of 8-chloro- N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine for use as defined above, or the pharmaceutical composition for use as defined above, wherein the equivalent level of the free base of 8-chloro- N-(4rczonn / zznz / E / YiAi 180 (trifluoromethoxy)phenyl)quinolin-2-amine in a sample of blood, plasma, tissue, saliva and / or serum from the patient is measured during use. According to another embodiment, the present invention also relates to co-crystals of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine for use as defined above, pharmaceutically acceptable salts of 8 -chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine for use as defined above, or the pharmaceutical composition for use as defined above, where the use is proposed for a patient whose equivalent level of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine free base in a patient's blood, plasma, tissue, saliva and / or serum sample is measured during use. According to yet another embodiment, the present invention also relates to co-crystals of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine for use as defined above, pharmaceutically acceptable salts of 8- chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine for use as defined above, or the pharmaceutical composition for use as defined above, wherein the presence and / or expression level of miR -124 in the patient's blood and / or tissue sample, is measured before and / or during use, in particular to monitor the effectiveness of use and / or rczonn / zznz / E / YiAi 181 the response to use. Next, the present invention will be described in more detail with reference to the following examples. These examples are provided to illustrate the present invention and should not be construed as limiting the scope and spirit of the present invention. Examples Material and methods I. Differential scanning calorimetry (DSC) - TA INSTRUMENTS Q200 Sealed aluminum sample pan (not airtight) - Atmosphere: Nitrogen - Heating rate: 10K / min - Data processing: UNIVERSAL ANALYSIS 2000 v4.3 The samples were analyzed by DSC from 0 °C temperature to 300 ’C. II. X-ray powder diffraction (XRPD) - Bruker D8 Advance diffractometers; - Copper anticathode, voltage 35 KV, intensity 40 mA - Bragg-Brentano configuration, fixed sample - Analysis interval: 2o to 40° - Step increment: 0.04° - Measurement time per step: 1 s Experimental treatment of data by rczonn / zznz / E / YiAi 182 EVA software (v 11.0) The positions and intensities of the X-ray peaks are extracted from the analyzed samples. III. HPLC-UV method The samples were analyzed by HPLC-UV according to the following method: - Instrument: Agilent 1200 and 1100 with PDA detector - Column: Waters XTerra MS C18 3.5pm 4.6x50 mm - Flow rate: 1.5 ml / min - UV detection: 220nm, 270nm, 290nm - Column temperature: 40 °C - Injection volume: 1 μΐ - Mobile phase: gradient with solutions A and B prepared according to the following: - Eluent A: Ultrapurified water adjusted to pH2 with 85% orthophosphoric acid - Eluent B: Acetonitrile. Table 7a below shows the HPLC gradient method used for kinetic solubility measurements and the in vitro dissolution / precipitation model. Table 7a rczonn / zznz / E / YiAi Time in minutes % A % B 0 90 10 4 5 95 7.9 5 95 8 90 10 183 Time in minutes % A % B 10 90 10 rczonn / zznz / E / YiAi Example 1: Preparation of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine: L-proline 6.6 mg of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine were mixed with 1.6 mg of Lproline as co-former and 2 μΐ of acetonitrile and then the mixture obtained was ground at 20 hz for 45 min. using a Retsch MM200 instrument to obtain 7 mg of a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine: Lproline. The co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline was characterized by X-ray powder diffraction (XRPD) to confirm the formation of co-crystals and by calorimetry differential scanning (DSC) to determine the thermal behavior of new solid forms. More particularly, this 8-chloro-N(4-(trifluoromethoxy)phenyl)quinoline-2-amine:L-proline co-crystal has an X-ray powder diffractogram showing peaks expressed as degree angle 2-Theta a 16.5; 20.6; 21.4; and 22.1 (each time +0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 11.0; 15.9; 18.3; and 19.4 (each time ±0.2); and even optionally also the following peaks Additional 184 expressed as angle of degrees 2-Theta 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 1 and / or having a single endotherm with an onset temperature of 172.0 °C (±2 °C ). The same example was carried out, except that acetonitrile was replaced by methanol as the polar organic solvent and a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine: L-proline was obtained. . Example 2: Preparation of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine: gentisic acid 8.9 mg of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine was mixed with 2.3 mg of gentisic acid as a co-former and 2 μl of acetonitrile and then the obtained mixture was ground at 20 hz for 45 min using a Retsch MM200 instrument to obtain 7 mg of a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine: gentisic acid. The co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine: gentisic acid was characterized by X-ray powder diffraction (XRPD) to confirm the formation of co-crystals and by differential calorimetry scanning (DSC) to determine the thermal rczonn / zznz / E / YiAi behavior of the new solid forms. 185 More particularly, this co-crystal of 8-chloro-N(4-(trifluoromethoxy)phenyl)quinoline-2-amine: gentisic acid has an X-ray powder diffractogram showing peaks expressed as angle degrees 2-Theta to 7.9 ; 14.0; 15.2; and 25.2 (each time ±0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 15.8; 16.9; 18.5; 19.9; 20.3; 23.0 and 24.7 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 2 and / or having a single endotherm with an onset temperature of 133.0 °C (±2 °C) . The same example was carried out except that acetonitrile was replaced by methanol as the polar organic solvent and a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine: gentisic acid was obtained. Example 3: Preparation of a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine: malonic acid 5.8 mg of 8-chloro-N- (4(trifluoromethoxy)phenyl)quinolin-2-amine were mixed with 1.5 mg of malonic acid as co-former and 2 μΐ of acetonitrile and then the mixture obtained was ground at 20 hz for 45 min using a Retsch MM200 instrument to obtain 7 mg of a co-crystal of 186 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine: malonic acid. The co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine: malonic acid was characterized by X-ray powder diffraction (XRPD) to confirm the formation of co-crystals and by differential calorimetry scanning (DSC) to determine the thermal behavior of new solid forms. More particularly, this co-crystal of 8-chloro-N(4-(trifluoromethoxy)phenyl)quinoline-2-amine:malonic acid has an X-ray powder diffractogram showing peaks expressed as angle degrees 2-Theta to 9.5 ; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; and 25.6 (each time ±0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 19.0; 21.4; 24.6; 26.8; 27.6; and 29.9 (each time ±0.2); and even optionally further the following additional peaks expressed as degree angle 2-Theta 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 3 and / or having a single endotherm with an onset temperature of 109.0 °C (±2 °C) . The same example was carried out except that acetonitrile was replaced by methanol as the polar organic solvent and a co-crystal of 8-chloro-N-(4rczonn / zznz / E / YiAi 187 (trifluoromethoxy)phenyl)quinoline-2-amine: malonic acid. Example 4: Preparation of a co-crystal of 8-Chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine: 4,4'-bipyridine 8.6 mg of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine were mixed with 2.4 mg of 4,4'bipyridine as co-former and 2 μΐ of acetonitrile and then the mixture obtained was ground at 20 hz for 45 min using a Retsch MM200 instrument to obtain 7 mg of a co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine: 4,4'bipyridine. The co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinoline-2-amine: 4,4'-bipyridine was characterized by X-ray powder diffraction (XRPD) to confirm the formation of co-crystals and by differential scanning calorimetry (DSC) analysis to determine the thermal behavior of new solid forms. More particularly, this 8-chloro-N(4-(trifluoromethoxy)phenyl)quinoline-2-amine:4,4'-bipyridine co-crystal has an X-ray powder diffractogram showing peaks expressed as angle of degrees 2 -Theta at 12.0; 19.2; 21.2; and 24.3 (each time ±0.2), and which can optionally also display the following additional peaks expressed as a 2-Theta degree angle: 16.0; 17.0; 17.8; 20.3; 22.5; and 22.7 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 8.5; rczonn / zznz / E / YiAi 188 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2), optionally further characterized by an X-ray powder diffractogram as illustrated in Figure 4 and / or having a single endotherm with an onset temperature of 127.0 °C (±2 °C ). The same example was carried out except that acetonitrile was replaced by methanol as the polar organic solvent and a co-crystal of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine was obtained: 4,4' -bipyridine. Example 5: Preparation of an Anhydrous Crystalline ABX464 Hemi-Napadisylate Salt 11.9 mg of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine was dissolved in 500 μΐ of methanol. To this mixture, 175 μΐ of 0.1 M naphthalene-1,5disulfonic acid (counterion) in ethanol was added to obtain a molar ratio of ABX464:counterion of 2:1. The mixture preparation was stirred magnetically at room temperature (25 °C) for ½ hour. The solvents were evaporated at room temperature (25 °C) under a flow of Nz gas. Acetone was then added as a crystallization solvent (1180 μl of acetone) into the tube. The tube was then sealed to prevent evaporation of the crystallization solvent and heated for 1 h at 60 °C while stirring the solution using a magnetic bar. To induce crystallization of the products, the rczonn / zznz / E / YiAi 189 tube was then cooled at a rate of 0.1 °C / min and 5 °C while the solution was stirred using a magnetic bar. The obtained suspension was then filtered under a 0.2 pm mesh and then dried under vacuum at 40 °C. 8 mg of an anhydrous crystalline ABX464 hemi-napadisylate salt are thus obtained. As already mentioned in the present text, this salt has an X-ray powder diffractogram showing peaks expressed as angle degrees 2-Theta to 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5 and 26.3 (each time ±0.2), and optionally also displays the following additional peaks expressed as 2-Theta degree angle: 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 25.2; and 25.9 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2), as illustrated in Figure 5 (X-ray powder diffractogram) and / or having a single endotherm with an initial temperature of 269.0 °C (±2 °C). A characteristic X-ray powder diffractogram of an anhydrous crystalline ABX464 hemi-napadisylate salt is shown in Figure 5. Example 6: Preparation of Anhydrous Crystalline ABX464 Esylate Salt 11.4 mg of 8-chloro-N-(4 rczonn / zznz / E / YiAi were dissolved 190 (trifluoromethoxy)phenyl)quinoline-2-amine in 500 μΐ methanol. To this mixture, 337 μΐ of 0.1 M ethanesulfonic acid (counterion) in water / ethanol (1 / 10) was added to obtain a molar ratio of ABX464:counterion of 1:1. The mixture preparation was stirred magnetically at room temperature (25 °C) for one hour. The solvents were evaporated at room temperature (25 °C) under a flow of N2 gas. Ethyl acetate was then added as a crystallization solvent (480 μΐ ethyl acetate) to the tube. The tube was then sealed to prevent evaporation of the crystallization solvent and heated for 1 h at 60 °C while stirring the solution using a magnetic bar. To induce crystallization of the products, the tube was then cooled at a rate of 0.1 °C / min and 5 °C while the solution was stirred using a magnetic bar. The obtained solution was then evaporated under a flow of N2 gas at room temperature. 12 mg of an anhydrous crystalline ABX464 esylate salt are thus obtained. As already mentioned in the present text, this salt has an X-ray powder diffractogram showing peaks expressed as angle degrees 2-Theta to 12.2; and 22.2 (each time +0.2), and optionally also displays the following additional peaks expressed as 2-Theta degree angle: 6.2; 12.9; 13.1; 15.3; 16.3; 18.2; 18.6; 19.5; 20.0; and 20.7 (each rczonn / zznz / E / YiAi 191 time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 10.1; 15.8; 17.7; 17.9; 20.3; and 21.4 (each time ±0.2), as illustrated in Figure 6 (X-ray powder diffractogram) and / or having a single endotherm with an onset temperature of 108.0 °C (±2 °C). A characteristic X-ray powder diffractogram of the anhydrous crystalline ABX464 esylate salt is shown in Figure 6. Example 7: Preparation of crystalline hemi-THF (tetrahydrofuran) solvate of the hemi-napadisylate salt of ΆΒΧ464 10.6 mg of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine was dissolved in 500 μΐ of methanol. To this mixture, 313 μΐ of 0.1 M naphthalene-1,5disulfonic acid (counterion) in ethanol was added to obtain a molar ratio of ABX464:counterion of 2:1. The mixture preparation was stirred magnetically at room temperature (25 °C) for one hour. The solvents were evaporated at room temperature (25 °C) under a flow of N2 gas. THE was then added as a crystallization solvent (1030 μΐ THE) to the tube. The tube was then sealed to prevent evaporation of the crystallization solvent and heated for 1 hour at 60 °C while stirring the solution using a rczonn / zznz / E / YiAi bar. 192 magnetic. To induce crystallization of the products, the tube was then cooled at a rate of 0.1 °C / min and 5 °C while the solution was stirred using a magnetic bar. The obtained suspension was then filtered under a 0.2 pm mesh and then dried under vacuum at 40 °C. 8 mg of a crystalline hemi-THF (tetrahydrofuran) solvate of the hemi-napadisylate salt of ABX464 are thus obtained. As already mentioned in the present text, this salt has an X-ray powder diffractogram showing peaks expressed as angle degrees 2-Theta to 8.4; 12.3; 14.0; 19.2; 21.3; 22.6 and 24.6 (each time ±0.2), and optionally also displays the following additional peaks expressed as 2-Theta degree angle: 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9 and 25.2 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angle: 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2), as illustrated in Figure 7 (X-ray powder diffractogram) and / or having a single endotherm with an onset temperature of 172.0 °C (±2 °C). A characteristic X-ray powder diffractogram of a crystalline hemi-THF solvate of the heminapadisylate salt of ABX464 is shown in Figure 7. Example 8: Pharmaceutical compositions in capsule form according to the invention comprising a co-crystal of ABX464 such as rczonn / zznz / E / YiAi 193 as defined in the invention The following capsule was prepared with the ingredients in the respective amounts as specified below in table 8. rczonn / zznz / E / YiAi Table 8 Ingredients Function Amount (in mg) / unit Co-crystal of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin2-amine: 4,4'-bipyridine as prepared according to example 4 Active ingredient 20.00 equivalents of ABX464 Mannitol Filler 120.00 Pregelatinized starch Binder 10.00 Talc Slipper 0.85 Zinc stearate Lubricant 0.85 White opaque hard gelatin capsule, size 1 sold by Capsugel Belgium NV (Body composition: 2% ΉΟ2 and c.s. 100% gelatin (origin of bovine and / or pork) Composition of the cap: 2% T¡02 and c.s. 100% gelatin (bovine and / or porcine origin). Capsule cover 1 unit The pharmaceutical compositions according to the invention are useful in the prevention and / or treatment of inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH (non-alcoholic steatohepatitis) and multiple sclerosis, diseases caused by a virus and / or cancer or dysplasia. Example 9: Pharmaceutical composition in capsule form according to the invention comprising a pharmaceutically acceptable salt of ABX464 as defined in the invention 194 The following capsule was prepared with the ingredients in the respective quantities as specified below in table 9. rczonn / zznz / E / YiAi Table 9 Ingredients Function Amount (in mg) / unit Crystalline hemi-THF solvate of the heminapadisylate salt of ABX464 as prepared according to example 7 Active ingredient 20.00 equivalents of ABX464 Mannitol Filler 120.00 Pregelatinized starch Binder 10.00 Talc Slipper 0.85 Zinc stearate Lubricant 0.85 White opaque hard gelatin capsule, size 1 sold by Capsugel Belgium NV (Body composition: 2% T¡02 and c.s. 100% gelatin (bovine and / or porcine origin) Cap composition: 2% T¡02 and c.s. 100% gelatin (bovine and / or porcine origin). Capsule cover 1 unit The pharmaceutical compositions according to the invention are useful in the treatment and / or prevention of inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, NASH and multiple sclerosis, diseases caused by a virus and / or cancer or dysplasia. Example 10: Preparations and kinetic measurement of the solubility of the anhydrous salt of hemi-napadisylate of ABX464 and co-crystal of ABX464:L-proline according to the description in comparison with the crystalline form I of ABX464, in two specific aqueous media different at the time of 195 selected sampling The hemi-napadisylate anhydrous salt of ABX464 and the co-crystal of ABX464:L-proline according to the description that were tested were prepared according to the two protocols detailed below (see respectively example 10a and example 10b ). Example 10a: Preparation of anhydrous salt of ΆΒΧ464 hemi-napadisylate The synthesis of the hemi-napadisylate anhydrous salt of ABX464 was performed according to the following protocol: - 200 mg of crystalline form I of ABX464 were weighed in a 20 ml glass vial; - 10 ml of methanol was added to the glass vial to solubilize the crystalline form I of ABX464 using 15 min of magnetic stirring at room temperature; - Next, the methanol solution of ABX464 was filtered through a 0.45 pm PTFE filter; - 5.9 ml of the 0.05 M ethanol solution of naphthalene-1,5disulfonic acid were added dropwise at room temperature; - The solution was stirred magnetically for 60 minutes at room temperature (a light yellow solution was observed); - Next, the solvents were evaporated under a flow of N2 gas at room temperature (a solid rczonn / zznz / E / YiAi was obtained 196 slightly yellow); - 10 ml of acetone was added into the glass vial at room temperature to crystallize the heminapadisylate salt of ABX464 overnight while the suspension was stirred magnetically; - The suspension was filtered through a 0.2 pm cellulose mesh filter (a slightly yellow solid was obtained); - The solid obtained was finally dried under vacuum at room temperature to obtain the anhydrous ABX464 hemi-napadisylate salt. To characterize this salt, an X-ray powder diffraction analysis was carried out. The corresponding XRPD pattern was characteristic of a crystalline solid and was comparable to that illustrated in Figure 5. Example 10b: Preparation of ABX464: co-crystal of L-proline The synthesis of the ABX464:L-Proline co-crystal was carried out according to the following protocol: - The physical powder mixture was prepared by mixing 200 mg of ABX464 crystalline form I and 68 mg of L-proline (1 / 1 molar stoichiometry) in a 10 ml stainless steel grinding container; - 2 stainless steel grinding balls with a diameter of 5 mm were introduced into the grinding container; rczonn / zznz / E / YiAi - 130 μΐ of methanol were added; 197 - Immediately after the addition of the solvent drops, the container was sealed; - The container was then placed in the grinding instrument (Retsch MM200) for 45 minutes of grinding at 20 Hz; - The co-crystal of ABX464:L-Proline was thus obtained. To characterize this co-crystal, X-ray powder diffraction analysis was performed. The corresponding XRPD pattern was characteristic of a crystalline solid and was comparable to that illustrated in Figure 1. Example 10c: Kinetic solubility in two aqueous media Kinetic solubility measurements for ABX464 crystalline form I, for the anhydrous ABX464 hemi-napadisylate salt, and for the L-proline co-crystal of ABX464, respectively, have been carried out using the following protocol. Kinetic solubility protocol Sample preparation for kinetic solubility measurements at room temperature protected from light at a target concentration of 2 mg / mL (ABX464 equivalent): - In a 4 ml glass vial, 2 mg of the ABX464 equivalent of the tested material was weighed; - At room temperature, 1 ml of the selected medium was added (see details below); - At room temperature protected from light, rczonn / zznz / E / YiAi 198 performed an orbital shake (see below); - At the selected sampling time (5 min, 30 min, 2 h, 4 h and 24 h), the soluble and non-soluble fraction was separated by filtration over a 0.45 pm PTFE membrane; - Immediately after filtration, HPLC-UV dosing of the resulting filtrate was carried out against single-point external calibration. The HPLCUV method selected for these measurements was described previously (see also Table 7a above). - Preparation of the reference solution ABX464 at 1 mg / ml: - 1 mg of crystalline form I of ABX464 was weighed; - was solubilized with DMSO until obtaining a clear 1 mg / ml DMSO solution. These two specific aqueous media are more particularly: FaSSIF (specifically, a simulated intestinal fluid in a fasting state) pH = 6.5 + 1 wt% PVPVA (polyvinylpyrrolidone-vinyl acetate: a precipitation inhibitor); and FeSSIF (specifically, a simulated intestinal fluid in the fed state) pH =5.0+1% by weight of PVPVA (a precipitation inhibitor) To make 5 mi of FaSSIF, the steps were as follows: rczonn / zznz / E / YiAi 199 - Weigh 11.2 mg of SIF powder, add 175 μΐ of the concentrated FaSSIF buffer solution and make up to 5.0 ml with ultrapurified water; let rest for 2 hours; and add 1% w / w of PVPVA. To make 5 mi of FeSSIF the steps were as follows: - weigh 56.0 mg of SIF powder, add 350 μΐ of the concentrated FeSSIF buffer solution and make up to 5.0 ml with ultrapurified water; and add 1% w / w of PVPVA. Kinetic solubility results The kinetic solubility results of ABX464 crystalline form I, anhydrous ABX464 heminapadisylate salt and ABX464:L-proline co-crystal in FassiF and FessiF media at different sampling times are shown in the table 10 below. rczonn / zznz / E / YiAi Table 10 Kinetic solubility (pg / mi) Medium Sampling times Crystalline form 1 of ABX464 Heminapadilitate salt of ABX464 anhydrous Co-crystal of ABX464:L-Proline FassiF pH 6.5 + 1% PVPVA 5 min 6 70 80 30 min 22 116 114 2h 47 149 118 4h 62 206 107 24h 72 432 98 5 min 54 396 869 200 FessiF pH 5 + 1% PVPVA 30 min 153 782 1064 2h 297 1053 1162 4h 358 1055 1277 24h 419 1517 1279 rczonn / zznz / E / YiAi As a conclusion to these solubility measurements, the following general observations can be highlighted: - In both media and at each time, there is a greater solubility of the anhydrous salt of hemi-napadisylate of ABX464 and the co-crystal of ABX464:L-Proline compared to the crystalline form I of ABX464. - There is a significantly higher solubility of all solid forms in the FeSSIF pH5.0+ 1% PVPVA medium. Finally, it was observed that the solubility of: - The hemi-napadisylate salt of anhydrous ABX464 in FeSSIF + 1% PVPVA medium quickly reaches a plateau at -1.05 mg / ml at 2 h before continuing to increase to -1.52 mg / ml at 24 h. The co-crystal of ABX4 64 : L-proline in FeSSIF + 1% PVPVA medium quickly reaches a plateau at −1.16 mg / mL at 2 h before further increasing weakly to −1.28 mg / mL at 24 h. - Crystalline form I of ABX464 in FeSSIF + 1% PVPVA medium reaches a plateau at -0.30 mg / ml at 2 h before further increasing weakly to -0.42 mg / ml at 24 h. Example 11: Measurement of solubility in the compartment 201 Intestinal fasting human in vitro model of two-step dissolution-precipitation of the heminapadisylate salt of anhydrous ΆΒΧ464 compared to crystalline form I of ABX464 ABX464 crystalline form I and the anhydrous ABX464 hemi-napadisylate salt were evaluated in the human in vitro two-step dissolution / precipitation model. The anhydrous hemi-napadisylate salt of ABX464 used in this test was that prepared according to the protocol detailed in example 10a above. The crystalline form I of ABX464 used in this test was the same as that used in example 10 above. The model consists of the following steps: - Dispensing of the selected material into the simulated gastric medium under fasting conditions containing 1% by weight PVPVA (precipitation inhibitor) and after 30 minutes, - Dilution of the suspension obtained by the simulated fasting intestinal environment. Using this model, the dissolution of selected materials (crystalline form I of ABX464, or the anhydrous hemi-napadisylate salt of BX464) in a gastric medium and the risk of precipitation of the API (Active Pharmaceutical Ingredient) in the intestinal compartment were evaluated. The crystalline nature of solid waste rczonn / zznz / E / YiAi 202 collected at the end of each step (gastric and intestinal) has been determined by XRPD after centrifugation (15 min at 18000 rpm). Protocol for the dissolution / precipitation model under human fasting conditions - in 6 different vials, 4.0 mg equivalent of ABX464 of the selected material is weighed - Measurement of solubility in the gastric compartment (also called G) at 15 min (G 15min) and 30 min (G 30min) which includes the following steps: - Addition of 1 ml of FaSSGF pH 1.2 medium containing 1% PVPVA by weight (target concentration of ABX464 = 4 mg / ml) in the 6 vials, - Mixed with swirl stirring at 37 °C. - At times of 15 min and 30 min, considering one vial (vials labeled G 15min and G 30min respectively) and for each vial - observe the suspension appearance, - centrifuge for 5 min at 18000 rpm and filter on a 0.45 pm filter (Millex LCR filter Ref. SLCR0.13NK). - Measure the pH of the supernatant, - Dosage of the soluble fraction of ABX464 by HPLC, rczonn / zznz / E / YiAi - Record the XPRD pattern in the sample 203 final time point. - Measurement of solubility in the intestinal compartment (also called I) after 15 min (vial I 15 min), 30 min (vial I 30 min), 60 min (vial I 60 min) and 120 min (vial I 120 min ) which includes the following steps: - Add 1 ml of FaSSIF medium x2 pH 6.5 / sodium bicarbonate 90 / 10) to the remaining 4 vials (target concentration of ABX464 = 2 mg / ml) - Mixed with swirl stirring at 37 °C. Sometimes 15 min, 30 min, 60 min and 120 min, considering one vial (vials labeled I 15 min, I 30 min, I 60 min and I 120 min respectively) and for each vial - observe the appearance of suspension, - centrifuge 5 min at 18000 rpm and filter over a 0.45 pm filter (Millex LCR filter Ref. SLCR0.13NK). - Measure the pH of the supernatant, - Dosage of the soluble fraction of ABX464 by HPLC, - Record the XPRD pattern at the final time point sample. Composition and preparation of biorelevant media under fasting conditions (see tables 11 and 12): - Fasting gastric medium = FaSSGF pH = 1.2 / PVPVA rczonn / zznz / E / YiAi 204 at 1% w / v Table 11 rczonn / zznz / E / YiAi Product Concentration Preparation (500 ml) NaCl 34 nM 1.0 g of sodium chloride (NaCl) was weighed into approximately 400 ml of deionized water. 5 g of PVPVA were added. NaCl and PVPVA were dissolved by magnetic stirring. The pH was adjusted to 1.2 with HCl. Then it was taken up to 500 ml with deionized water. HCI c.s. up to pH 1.2 PVPVA 1% by weight water q.s. up to 500 mi Fasting Intestinal Medium (FaSSIF X2 pH=6.5 / sodium bicarbonate at 80 g / 1 90 / 10 v / v). Composition / Preparation of FaSSIF x2 (2-fold concentrated medium to account for dilution in the fasting model): Table 12 Product Concentration Preparation (500 ml) Na Taurocholate (TC) 6 mM 1) Buffer preparation: dissolved in approximately 0.57 I of deionized water - 2 x 0.21 = 0.42 g of sodium hydroxide (NaOH) granules - 2 x 1.98 = 3.95 g of NaH2PO4,2H2O - 2 x 3.1 = 6.19 g of sodium chloride (NaCl) - the pH was adjusted to 6.5 with 1N NaOH or HC11N. - It was brought to its volume (0.51) with purified water at room temperature. 2) SIF powder (from Biorelevant) was added - 2x1.12 = 2.24 g of SIF powder was weighed. Lecithin SI00 (L) 1.5 mM NaH2PO4, 2H2O 65.9 mM NaCl 212 mM 1N NaOH or 1N HCl q.s. pH 6.5 water q.s. 500 mi 205 - 0.251 of the buffer was added at room temperature. - The powder was stirred until it was completely dissolved. - It was brought up to 0.5 1. Observations: Leave it at rest for 2 hours, in stable conditions 48 hours at room temperature rczonn / zznz / E / YiAi The mixture of FaSSIF X2 / sodium bicarbonate 80 g / 1 (90 / 10; v / v) was prepared to maintain the pH equal to 6.5 in the intestinal compartment after dilution. Results from the fasting human two-step dissolution / precipitation model Solubility values ​​were obtained for ABX464 crystalline form I and the anhydrous ABX464 hemi-napadisylate salt in the two-step dissolution / precipitation human fasting model as indicated in Table 13 to Table 16 below. XRPD patterns recorded for solid residues collected at the last time points in the gastric (G 30 min) and intestinal (I 120 min) compartments of the fasting dissolution / precipitation tests were performed for crystalline form I of ABX464 , and the hemi-napadisylate anhydrous salt of ABX464 and were reported in Figure 8 (bottom line) and Figure 9 (bottom line) respectively. In Figure 8, it was also included for comparison 206 an X-ray powder diagram illustrating crystal form I of ABX464 (top line). Also included for comparison in Figure 9 are two powder The data and results (solubility measured in a fasting model with 1% PVPVA in FaSSGF pH 1.2) for ABX464 crystal form I are compiled in Table 13 and Table 14 below. rczonn / zznz / E / YiAi 207 rczonn / zznz / E / YiAi Table 13 Vials Time (min) Mass of active ingredient (AP)(mg) Mass of AP in active form (mg) G 15 min 15 4.09 4.09 G30 min 30 4.07 4.07 115min 45 4.16 4.16 I 30 min 60 4.09 4.09 I 60 min 90 4.02 4.02 1120 min 150 4.23 4.23 Table 14 Vials Gastric or intestinal volume (mi) Observation (at a given time) PH (at a given time) Target concentration (mg / ml) Soluble fraction (mg / ml) G15 min 1 Clear and colorless, white particles in suspension 1.2 4.09 0.06 G30 min 1 Clear and colorless, white particles in suspension 1.2 4.07 0.07 115 min 1 Clear and colorless, white particles in suspension 6.3 2.08 0.06 I 30 min 1 Clear and colorless, white particles in suspension 6.3 2.05 0.07 I 60 min 1 Clear and colorless , white particles in suspension 6.3 2.01 0.07 I 120 min 1 Clear and colorless, white particles in suspension 6.3 2.12 0.08 208 The data and results (solubility measured in a fasting model with 1% PVPVA in FaSSGF pH 1.2) for the anhydrous ABX464 hemi-napadisylate salt are compiled in the following Table 15 and Table 16. rczonn / zznz / E / YiAi Table 15 Vials Time (min) Mass of active ingredient (AP)(mg) Mass of AP in active form (mg) G 15 min 15 5.88 4.11 G 30 min 30 5.78 4.04 115 min 45 5.88 4.11 I 30 min 60 5.75 4.02 I 60 min 90 5.78 4.04 1120 min 150 5.88 4.11 Table 16 Vials Gastric or intestinal volume (mi) Observation (at a given time) pH (at a given time) Target concentration (mg / ml) Soluble fraction (mg / ml) G 15 min 1 Opalescent beige solution with particles in suspension 1.2 4.11 0.05 G30 min 1 Opalescent beige solution with suspended particles 1.2 4.04 0.06 115 min 1 Opalescent beige solution with 6.2 2.06 0.17 209 Vials Gastric or intestinal volume (mi) Observation (at a given time) pH (at a given time) Target concentration (mg / ml) Soluble fraction (mg / ml) particles in suspension 1 30 min 1 Opalescent beige solution with particles in suspension 6.2 2.01 0.23 1 60 min 1 Opalescent beige solution with suspended particles 6.2 2.02 0.32 1 120 min 1 Opalescent beige solution with suspended particles 6.2 2.06 0.43 rczonn / zznz / E / YiAi From these results, the following points can be highlighted: - In the intestinal compartment at pH 6.5: - No significant evolution of the soluble fraction of ABX464 from ABX464 crystalline form I in the intestinal compartment (~80 pg / ml) and no conversion of the crystalline phase detected by XRPD. - From the anhydrous ABX464 hemi-napadisylate salt, a significant increase in the soluble fraction of ABX464 is observed in the intestinal compartment (-430 pg / ml) and no crystalline phase conversion is detected by XRPD. 210 The main conclusions of these solubility studies, as shown in examples 10 and 11 above, were: - A significantly higher solubility for the hemi-napadisylate salt of ABX464 and for the co-crystal of ABX464:L-Proline, in Fassif and Fessif media, compared to crystalline form I of ABX464. - A significantly higher solubility of the hemi-napadisylate salt of ABX464 (~430 pg / ml) in the intestinal compartment of the human in vitro fasting two-step dissolution / precipitation model compared to the solubility of the crystalline form I of ABX464 (~80 pg / ml) in the intestinal compartment of this model. It is stated that in relation to this date, the best method known to the applicant to put the aforementioned invention into practice is the one that is clear from the present description of the invention.

Claims

1. Co-crystals of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, characterized in that they are selected from: 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine : L-proline having a powder X-ray diffractogram showing peaks expressed as 2-Theta degree angles at 16.5; 20.6; 21.4; and 22.1 (each time ±0.2), and optionally showing the following additional peaks expressed as 2-Theta degree angles: 11.0; 15.9; 18.3; and 19.4 (each time ±0.2); and even optionally the following additional peaks expressed as 2-Theta degree angles: 6.1; 12.2; 12.6; 13.3; 13.7; 15.4; 17.3 and 22.4 (each time ±0.2), optionally having as a particularity a powder X-ray diffractogram as illustrated in figure 1 and / or having a single endotherm with a starting temperature of 172.0 °C (±2 °C) ; 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine : gentisic acid having a powder X-ray diffractogram showing peaks expressed as 2-theta degree angles at 7.9; 14.0; 15.2; and 25.2 (each time ±0.2), and optionally showing the following additional peaks expressed as 2-Theta degree angles: 15.8; 16.9; 18.5; 19.9; 20.3; 23.0 and 24.7 (each time ±0.2); and even optionally the following additional peaks expressed as 2-Theta degree angles: 7.6; 14.7; 16.1; 19.7; 21.6; 22.0; 22.3; 23.7; and 24.0 (each time ±0.2), optionally having in addition a powder X-ray diffractogram as illustrated in Figure 2 and / or having a unique endotherm with a starting temperature of 133.0 °C (±2 °C); 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine: malonic acid having a powder X-ray diffractogram showing peaks expressed as a 2Theta degree angle at 9.5; 12.2; 15.8; 17.3; 19.7; 22.8; 24.8; and 25.6 (each time ±0.2), and which may optionally also show the following additional peaks expressed as 2-Theta degree angles: 19.0; 21.4; 24.6; 26.8; 27.6; and 29.9 (each time ±0.2); and even optionally also the following additional peaks expressed as 2-Theta degree angles: 16.8; 17.8; 20.9; 23.8; 28.0; and 29.6 (each time ±0.2), optionally having as a particularity a powder X-ray diffractogram as illustrated in Figure 3 and / or having a unique endothermy with a starting temperature of 109.0 °C (±2 °C); and 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2amine : 4,4'-bipyridine having an X-ray diffractogram rczonn / zznz / E / YiAi 213 in powder showing peaks expressed as 2-Theta degree angles at 12.0; 19.2; 21.2; and 24.3 (each time +0.2), and which may optionally further show the following additional peaks expressed as 2-Theta degree angles: 16.0; 17.0; 17.8; 20.3; 22.5; and 22.7 (each time ±0.2); and even optionally the following additional peaks expressed as 2-Theta degree angles: 8.5; 13.0; 15.7; 16.7; 20.9; 22.0; 23.1; 23.6 and 24.7 (each time ±0.2), optionally having as a particularity a powder X-ray diffractogram as illustrated in Figure 4 and / or having a single endotherm with a starting temperature of 127.0 °C (±2 °C).

2. A method for preparing an 8-chloroN-(4-(trifluoromethoxy)phenyl)quinolin-2-amine co-crystal according to claim 1, characterized in that it comprises the following steps: a) dissolving ABX464 in a solvent or a mixture of solvents; b) adding to the mixture thus obtained from step a) a co-former which may itself be already dissolved in a solvent or a mixture of solvents and which is selected from L-proline, malonic acid, gentisic acid and 4,4'-bipyridine to obtain an ABX464:co-former in a molar ratio between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and further rczonn / zznz / E / YiAi 215 characterized in that the solvent(s) of step a), step b) and / or step d) or of step a') and / or of step b') is / are any solvent conventionally used in the crystallization step, particularly is / are organic solvents, more particularly is / are selected from an aliphatic Ci-Ce alcohol,methyl ethyl ketone (also called butanone or MEK), cyclohexane, an alkane such as heptane, methylene chloride, chloroform, formic acid, DMSO, l-methyl-2-pyrrolidone, acetone, acetonitrile, tetrahydrofuran (THE), diethyl ether, dioxane, toluene, ethyl acetate, optionally mixed with water, and mixtures thereof, further more particularly selected from an aliphatic Ci-Ce alcohol, a mixture of fbO / aliphatic Ci-Ce alcohol, acetonitrile, and mixtures thereof, further more particularly selected from methanol, ethanol, isopropanol, HzO / methanol, HzO / ethanol, acetonitrile, and mixtures thereof.

4. A pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, characterized in that it includes a solvate and / or a hydrate thereof selected from lactate, oleate, oxalate, palmitate, stearate, valerate, pantothenate, picrate, butyrate, malonate, succinate, bitartrate, malate, mandelate, benzoate, edetate, gluceptate, gluconate, lactobionate, salicylate, disalicylate, mucate, pamoate, adipate, alginate, aspartate, camphorate, cyclopentanepropionate, digluconate, glucoheptonate, heptanoate, hexanoate, laurate, nicotinate, pamoate, pivalate, propionate, undecanoate and the like, phosphate and the like, camphorsulfonate, 2-hydroxyethanesulfonate, estolate, napsilate, esylate, napadisylate, dodecyl sulfate and the like, perchloric acid, boric acid, glycerophosphoric acid, nitric acid, persulfuric acid and the like, particularly selected from esylate and napadisylate,More particularly, it is selected from an anhydrous crystalline ABX464 hemina-napadisylate salt, an anhydrous crystalline ABX464 esylate salt, and a crystalline ABX464 hemina-napadisylate hemi-THF solvate.

5. A pharmaceutically acceptable salt of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, characterized in that it includes a solvate and / or a hydrate thereof according to claim 4, which is selected from: anhydrous crystalline ABX464 hemina-napadisylate salt having a powder X-ray diffractogram showing peaks expressed as 2-Theta degree angles at 9.8; 16.4; 18.2; 20.1; 21.2; 21.6; 23.5 and 26.3 (each time ±0.2), and optionally further showing the following additional peaks expressed as 2-Theta degree angles: 12.4; 13.1; 17.8; 20.9; 22.6; 24.5; 24.7; 25.2; and 25.9 (each time ±0.2); and even optionally the following additional peaks expressed as 2-Theta degree angle: 8.8; 13.3; 15.1; 17.2; 17.5; 19.4; 19.5; and 19.8 (each time ±0.2), as illustrated in Figure 5 (powder X-ray diffractogram) and / or having a single endotherm with an initial temperature of 269.0 °C (±2 °C); - anhydrous crystalline ABX464 esylate salt having a powder X-ray diffractogram showing peaks expressed as 2-Theta degree angles at 12.2 and 22.2 (each time ±0.2), and optionally showing further the following additional peaks expressed as 2-Theta degree angles: 6.2, 12.9, 13.1, 15.3, 16.3, 18.2, 18.6, 19.5, 20.0, and 20.7 (each time ±0.2); and even optionally further the following additional peaks expressed as 2-Theta degree angles: 10.1, 15.8, 17.7, 17.9, 20.3; and 21.4 (each time ±0.2), as illustrated in Figure 6 (powder X-ray diffractogram) and / or having a single endotherm with a starting temperature of 108.0 °C (±2 °C); and - crystalline hemi-THF solvate of the heminapadisylate salt of ABX464 having a powder X-ray diffractogram showing peaks expressed as 2Theta degree angle at 8.4; 12.3; 14.0; 19.2; 21.3; 22.6 and 24.6 (each time ±0.2), and optionally also shows the following additional peaks expressed as 2-Theta degree angles: 9.6; 13.0; 13.5; 14.8; 17.2; 17.8; 23.4; 24.1; 24.9 and 25.2 (each time ±0.2); and even optionally also the following additional peaks expressed as 2-Theta degree angles: 16.7; 18.1; 18.8; 19.5; 20.9 and 22.3 (each time ±0.2), as illustrated in Figure 7 (powder X-ray diffractogram) and / or having a single endotherm with a starting temperature of 172.0 °C (±2 °C).

6. The method for preparing a pharmaceutically acceptable salt of ABX464 including solvates or hydrates thereof according to claim 4 or 5, characterized in that it comprises the following steps: a) dissolving ABX464 in a solvent or a mixture of solvents; b) adding to the mixture thus obtained from step a) a counterion in the form of an acid which may itself be already dissolved in a solvent or a mixture of solvents to obtain a molar ratio of ABX464:counterion between 3:1 and 1:2, particularly between 5:2 and 1:2; more particularly between 2:1 and 1:2, and still more particularly 2:1 or 1:1; c) optionally evaporate the solvent(s) at a temperature between 0 °C and the boiling point of the selected solvent(s) or solvent(s) mixture from step a) and step b), particularly between room temperature and 60 °C, more particularly between room temperature and 50 °C;d) optionally add a solvent or a mixture of solvents, e) apply a temperature program; f) optionally filter; and g) then optionally dry at a temperature between ambient temperature and 60 °C to obtain the desired salt of ΆΒΧ464.; 7. The method according to claim 6, characterized in that the solvent of step a), step b) and / or step d) is any solvent conventionally used in the crystallization step, particularly organic solvents, more particularly selected from an aliphatic Ci-Ce alcohol, methyl ethyl ketone (also called butanone or MEK), cyclohexane, an alkane such as heptane, methylene chloride, chloroform, formic acid, DMSO, l-methyl-2-pyrrolidone, acetone, acetonitrile, tetrahydrofuran (THE), diethyl ether, dioxane, toluene, ethyl acetate, optionally in a mixture with water, and mixtures thereof, further more particularly selected from an aliphatic Ci-Cg alcohol, a mixture of tRO / Cg aliphatic alcohol, and mixtures thereof, further more particularly selected from methanol, ethanol, isopropanol, H2O / methanol, H2O / ethanol and mixtures thereof;and / or the acidic counterion from step b) is ethanesulfonic acid or naphthalene-1,5-disulfonic acid.; 8. The method according to any of claims 2, 3, 6 and 7, characterized in that step e) relating to the temperature program includes i) reflux heating at a temperature between ambient temperature and the boiling point of the solvent(s), particularly between ambient temperature and 60 °C and / or ii) reflux cooling at a temperature between 0 °C and 60 °C, particularly between 5 °C and 40 °C, more particularly between ambient temperature and 40 °C at a rate between 30 °C / min and 0.05 °C / min, particularly between 10 °C / min and 0.05 °C / min, more particularly between 5 °C / min and 0.05 °C / min.

9. The method according to any of claims 2, 3, 6, 7 and 8, characterized in that the filtration step f) is performed using conventional glass fibers, conventional cellulosic paper filters, PTFE (polytetrafluoroethylene), or PVDF (polyvinylidene fluoride), in particular cellulosic filter paper with a filtration mesh of 0.45 pm or 0.2 pm.

10. The method according to any of claims 2, 3, 6, 7, 8, 9 and 10, characterized in that step g) of drying is carried out under vacuum at a temperature between 30 °C and 60 °C, particularly at 40 °C or in an ambient atmosphere at a temperature between 30 °C and 60 °C, particularly at 40 °C.

11. A pharmaceutical composition, characterized in that it comprises at least one of the co-crystals of rczonn / zznz / E / YiAi 221 according to claim 1 and / or at least one of the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine including a solvate and / or a hydrate thereof according to claim 4 or 5, and at least one pharmaceutically acceptable excipient, in particular in the form of tablets, capsules, pills, lozenges, chewing gum, powders, granules, suppositories, emulsions, microemulsions, solutions such as aqueous solutions, suspensions such as aqueous suspensions, syrups, elixirs, ointments, drops, pastes, creams, lotions, gels, aerosols, inhalable substances or patches.

12. The 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine co-crystals according to claim 1, the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine according to claim 4 or 5, or the pharmaceutical composition according to claim 11, for use as a medicament.

13. The co-crystals of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine according to claim 1, the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine according to claim 4 or 5, or the pharmaceutical composition according to claim 11, for use in the prevention and / or treatment of an inflammatory disease.

14. The 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine co-crystals according to claim 1, the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine according to claim 4 or 5, or the pharmaceutical composition according to claim 11, for use in the treatment and / or prevention of cancer.

15. The co-crystals of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine or the pharmaceutical composition for use in accordance with any of claims 12 to 14, wherein the presence and / or expression level of miR-124 is measured in a patient blood and / or tissue sample before and / or during use, in particular to monitor the efficacy of use and / or the response to use.

16. The 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine co-crystals according to claim 1, the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine according to claim 4 or 5, or the pharmaceutical composition according to claim 11, for use in the treatment and / or prevention of diseases caused by viruses, in particular retroviruses and more particularly HIV, and more particularly for use in reducing the viral load in a patient infected with a virus, in particular HIV, or a virus-related condition, with a lasting effect and absence of resistance.

17. The 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine co-crystals according to claim 1, the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine according to claim 4 or 5, or the pharmaceutical composition according to claim 11, for use in the treatment and / or prevention of diseases caused by a virus belonging to the Coronaviridae family or by a Coronaviridae infection and related conditions, and in particular severe acute respiratory syndrome caused by SARSCoV or SARS-CoV-2 infection, including the strains responsible for COVID-19 and their mutants.

18. The co-crystals of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine, the pharmaceutically acceptable salts of 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine or the pharmaceutical composition for use in accordance with any of claims 12 to 17, wherein the level of equivalent of the 8-chloro-N-(4(trifluoromethoxy)phenyl)quinolin-2-amine free base, in the patient's blood, plasma, tissue, saliva, and / or serum sample, is measured during use.